<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE publicwhip [

<!ENTITY pound   "&#163;">
<!ENTITY euro    "&#8364;">

<!ENTITY agrave  "&#224;">
<!ENTITY aacute  "&#225;">
<!ENTITY egrave  "&#232;">
<!ENTITY eacute  "&#233;">
<!ENTITY ecirc   "&#234;">
<!ENTITY iacute  "&#237;">
<!ENTITY ograve  "&#242;">
<!ENTITY oacute  "&#243;">
<!ENTITY uacute  "&#250;">
<!ENTITY Aacute  "&#193;">
<!ENTITY Eacute  "&#201;">
<!ENTITY Iacute  "&#205;">
<!ENTITY Oacute  "&#211;">
<!ENTITY Uacute  "&#218;">
<!ENTITY Uuml    "&#220;">
<!ENTITY auml    "&#228;">
<!ENTITY euml    "&#235;">
<!ENTITY iuml    "&#239;">
<!ENTITY ouml    "&#246;">
<!ENTITY uuml    "&#252;">
<!ENTITY fnof    "&#402;">
<!ENTITY aelig   "&#230;">
<!ENTITY dagger  "&#8224;">
<!ENTITY reg     "&#174;">
<!ENTITY nbsp    "&#160;">
<!ENTITY shy     "&#173;">
<!ENTITY deg     "&#176;">
<!ENTITY middot  "&#183;">
<!ENTITY ordm    "&#186;">
<!ENTITY ndash   "&#8211;">
<!ENTITY mdash   "&#8212;">
<!ENTITY lsquo   "&#8216;">
<!ENTITY rsquo   "&#8217;">
<!ENTITY ldquo   "&#8220;">
<!ENTITY rdquo   "&#8221;">
<!ENTITY hellip  "&#8230;">
<!ENTITY bull    "&#8226;">

<!ENTITY acirc   "&#226;">
<!ENTITY Agrave  "&#192;">
<!ENTITY Aring   "&#197;">
<!ENTITY aring   "&#229;">
<!ENTITY atilde  "&#227;">
<!ENTITY Ccedil  "&#199;">
<!ENTITY ccedil  "&#231;">
<!ENTITY Egrave  "&#200;">
<!ENTITY Icirc   "&#206;">
<!ENTITY icirc   "&#238;">
<!ENTITY Igrave  "&#204;">
<!ENTITY igrave  "&#236;">
<!ENTITY ntilde  "&#241;">
<!ENTITY ocirc   "&#244;">
<!ENTITY oelig   "&#339;">
<!ENTITY Ograve  "&#210;">
<!ENTITY Oslash  "&#216;">
<!ENTITY oslash  "&#248;">
<!ENTITY Scaron  "&#352;">
<!ENTITY scaron  "&#353;">
<!ENTITY sup1    "&#185;">
<!ENTITY sup2    "&#178;">
<!ENTITY sup3    "&#179;">
<!ENTITY ugrave  "&#249;">
<!ENTITY Ugrave  "&#217;">
<!ENTITY yacute  "&#253;">
<!ENTITY frac12  "&#189;">
<!ENTITY micro   "&#181;">
<!ENTITY sbquo   "&#8218;">
<!ENTITY trade   "&#8482;">
<!ENTITY Dagger  "&#8225;">
]>

<publicwhip>

<source url="http://www.scottish.parliament.uk/business/pqa/wa-08/wa0325.htm"/>

<major-heading id="uk.org.publicwhip/spwa/2008-03-25.0.mh" nospeaker="True" url="http://www.scottish.parliament.uk/business/pqa/wa-08/wa0325.htm">Written Answers Tuesday 25 March 2008</major-heading>

<major-heading id="uk.org.publicwhip/spwa/2008-03-25.1.mh" nospeaker="True" url="http://www.scottish.parliament.uk/business/pqa/wa-08/wa0325.htm">Scottish Executive</major-heading>

<minor-heading id="uk.org.publicwhip/spwa/2008-03-25.S3W-10867.h" nospeaker="True" url="http://www.scottish.parliament.uk/business/pqa/wa-08/wa0325.htm#1">Access for People with Disabilities</minor-heading>

<ques id="uk.org.publicwhip/spwa/2008-03-25.S3W-10867.q0" speakerid="uk.org.publicwhip/member/80325" speakername="Patrick Harvie (Glasgow) (Green)" spid="S3W-10867" url="http://www.scottish.parliament.uk/business/pqa/wa-08/wa0325.htm#1">

  <p>To ask the Scottish Executive what kind of representation disabled people have in the governance of (a) the Mobility and Access Committee for Scotland and (b) Passenger View Scotland.</p>

</ques>


<reply id="uk.org.publicwhip/spwa/2008-03-25.S3W-10867.r0" speakerid="uk.org.publicwhip/member/80393" speakername="Stewart Stevenson" url="http://www.scottish.parliament.uk/business/pqa/wa-08/wa0325.htm#1">

  <p>(a) The Mobility and Access Committee for Scotland Regulations 2002 state that the convener and at least half of the total number of the committee, including the convener, be disabled persons according to the Disability Discrimination Act 1995.</p>

  <p>(b) We propose to prescribe that at least three of the 15 members of the Passenger View Scotland (PVS) be disabled persons according to the Disability Discrimination Act 1995.</p>

</reply>


<minor-heading id="uk.org.publicwhip/spwa/2008-03-25.S3W-10868.h" nospeaker="True" url="http://www.scottish.parliament.uk/business/pqa/wa-08/wa0325.htm#1">Access for People with Disabilities</minor-heading>

<ques id="uk.org.publicwhip/spwa/2008-03-25.S3W-10868.q0" speakerid="uk.org.publicwhip/member/80325" speakername="Patrick Harvie (Glasgow) (Green)" spid="S3W-10868" url="http://www.scottish.parliament.uk/business/pqa/wa-08/wa0325.htm#1">

  <p>To ask the Scottish Executive in what way disabled peoples&rsquo; voices will be given greater prominence in the governance structures of Passenger View Scotland, in light of that body assuming the functions of the Mobility and Access Committee for Scotland.</p>

</ques>


<reply id="uk.org.publicwhip/spwa/2008-03-25.S3W-10868.r0" speakerid="uk.org.publicwhip/member/80393" speakername="Stewart Stevenson" url="http://www.scottish.parliament.uk/business/pqa/wa-08/wa0325.htm#1">

  <p>We propose to prescribe that at least three members of Passengers&rsquo; View Scotland (PVS) will be disabled persons as determined by the Disability Discrimination Act 1995. We will shortly be inviting members of Mobility and Access Committee for Scotland (MACS) and their stakeholders to apply for the three new posts within the PVS. These appointments will be carried out in line with the Office of the Commissioner for Public Appointments in Scotland&rsquo;s code of practice.</p>

  <p>The addition of three members to PVS to represent disabled passengers will mainstream the issue and increase the profile of disability issues across a winder range of transport modes.</p>

</reply>


<minor-heading id="uk.org.publicwhip/spwa/2008-03-25.S3W-10823.h" nospeaker="True" url="http://www.scottish.parliament.uk/business/pqa/wa-08/wa0325.htm#2">Alcohol Misuse</minor-heading>

<ques id="uk.org.publicwhip/spwa/2008-03-25.S3W-10823.q0" speakerid="uk.org.publicwhip/member/80284" speakername="Richard Baker (North East Scotland) (Lab)" spid="S3W-10823" url="http://www.scottish.parliament.uk/business/pqa/wa-08/wa0325.htm#2">

  <p>To ask the Scottish Executive how much funding was spent on alcohol support services in Aberdeen during (a) 2002-03, (b) 2003-04, (c) 2004-05, (d) 2005-06 and (e) 2006-07.</p>

</ques>


<reply id="uk.org.publicwhip/spwa/2008-03-25.S3W-10823.r0" speakerid="uk.org.publicwhip/member/80379" speakername="Shona Robison" url="http://www.scottish.parliament.uk/business/pqa/wa-08/wa0325.htm#2">

  <p>NHS Grampian was provided with the amounts shown in the table for onward distribution to the Alcohol and Drug Action Teams (ADATs) for alcohol treatment services. No specific funds were made available for alcohol treatment services prior to 2004-05. Information on amounts spent in Aberdeen is not held centrally as this is a local decision.</p>

  <p><table width="25%" border="BORDER" cellpadding="2" cellspacing="0" bordercolor="#CCCCCC">
<tr>
<td width="33%" align="center" valign="top"><p align="center">2004-05</p></td>
<td width="33%" align="center" valign="top"><p align="center">2005-06</p></td>
<td width="33%" align="center" valign="top"><p align="center">2006-07</p></td>
</tr>
<tr>
<td width="33%" align="right" valign="top"><p align="right">&pound;212,000</p></td>
<td width="33%" align="right" valign="top"><p align="right">&pound;699,000</p></td>
<td width="33%" align="right" valign="top"><p align="right">&pound;699,000</p></td>
</tr>
</table></p>

  <p>Further information may be available in the Aberdeen City ADAT Corporate Action Plans which can be accessed from <a href="http://www.drugmisuse.isdscotland.org/dat/cap/dat.htm" target="_blank">http://www.drugmisuse.isdscotland.org/dat/cap/dat.htm</a>.</p>

</reply>


<minor-heading id="uk.org.publicwhip/spwa/2008-03-25.S3W-10824.h" nospeaker="True" url="http://www.scottish.parliament.uk/business/pqa/wa-08/wa0325.htm#2">Alcohol Misuse</minor-heading>

<ques id="uk.org.publicwhip/spwa/2008-03-25.S3W-10824.q0" speakerid="uk.org.publicwhip/member/80284" speakername="Richard Baker (North East Scotland) (Lab)" spid="S3W-10824" url="http://www.scottish.parliament.uk/business/pqa/wa-08/wa0325.htm#2">

  <p>To ask the Scottish Executive how much funding will be spent on alcohol support services in Aberdeen during the current spending review period.</p>

</ques>


<reply id="uk.org.publicwhip/spwa/2008-03-25.S3W-10824.r0" speakerid="uk.org.publicwhip/member/80379" speakername="Shona Robison" url="http://www.scottish.parliament.uk/business/pqa/wa-08/wa0325.htm#2">

  <p>The Scottish Government will provide &pound;2,014,386 in 2008-09 to NHS Grampian for alcohol treatment services and brief interventions. The detailed allocation of this is for the board and its partners to agree locally. Figures for future years are not available.</p>

</reply>


<minor-heading id="uk.org.publicwhip/spwa/2008-03-25.S3W-10898.h" nospeaker="True" url="http://www.scottish.parliament.uk/business/pqa/wa-08/wa0325.htm#3">Angling</minor-heading>

<ques id="uk.org.publicwhip/spwa/2008-03-25.S3W-10898.q0" speakerid="uk.org.publicwhip/member/80384" speakername="John Scott (Ayr) (Con)" spid="S3W-10898" url="http://www.scottish.parliament.uk/business/pqa/wa-08/wa0325.htm#3">

  <p>To ask the Scottish Executive whether it has plans to introduce rod licences.</p>

</ques>


<reply id="uk.org.publicwhip/spwa/2008-03-25.S3W-10898.r0" speakerid="uk.org.publicwhip/member/80340" speakername="Richard Lochhead" url="http://www.scottish.parliament.uk/business/pqa/wa-08/wa0325.htm#3">

  <p>There are currently no plans to introduce rod licences.</p>

</reply>


<minor-heading id="uk.org.publicwhip/spwa/2008-03-25.S3W-10807.h" nospeaker="True" url="http://www.scottish.parliament.uk/business/pqa/wa-08/wa0325.htm#4">Autism</minor-heading>

<ques id="uk.org.publicwhip/spwa/2008-03-25.S3W-10807.q0" speakerid="uk.org.publicwhip/member/80313" speakername="Murdo Fraser (Mid Scotland and Fife) (Con)" spid="S3W-10807" url="http://www.scottish.parliament.uk/business/pqa/wa-08/wa0325.htm#4">

  <p>To ask the Scottish Executive whether it will undertake research to establish levels of mitochondrial dysfunction in the autism population in Scotland.</p>

</ques>


<reply id="uk.org.publicwhip/spwa/2008-03-25.S3W-10807.r0" speakerid="uk.org.publicwhip/member/80379" speakername="Shona Robison" url="http://www.scottish.parliament.uk/business/pqa/wa-08/wa0325.htm#4">

  <p>The Scottish Government and the Medical Research Council (MRC) have taken forward a jointly funded research programme in relation to autism, based on the agenda outlined in the MRC review of autism research. The MRC has now committed over &pound;3 million to new research. The awards range from clinical investigations in children and adults, to environmental risk factors, brain imaging and intervention studies. The Chief Scientist Office has also funded a number of studies into autism.</p>

  <p>No research is currently planned on the explicit issue of levels of mitochondrial dysfunction in the autism population in Scotland. However, the Chief Scientist Office is open to proposals for further studies.</p>

</reply>


<minor-heading id="uk.org.publicwhip/spwa/2008-03-25.S3W-10890.h" nospeaker="True" url="http://www.scottish.parliament.uk/business/pqa/wa-08/wa0325.htm#5">Enterprise</minor-heading>

<ques id="uk.org.publicwhip/spwa/2008-03-25.S3W-10890.q0" speakerid="uk.org.publicwhip/member/80369" speakername="Elaine Murray (Dumfries) (Lab)" spid="S3W-10890" url="http://www.scottish.parliament.uk/business/pqa/wa-08/wa0325.htm#5">

  <p>To ask the Scottish Executive what definitions have been agreed with COSLA, Scottish Enterprise and Highlands and Islands Enterprise regarding what constitutes (a) local, (b) regional and (c) national economic regeneration projects.</p>

</ques>


<ques id="uk.org.publicwhip/spwa/2008-03-25.S3W-10891.q1" speakerid="uk.org.publicwhip/member/80369" speakername="Elaine Murray (Dumfries) (Lab)" spid="S3W-10891" url="http://www.scottish.parliament.uk/business/pqa/wa-08/wa0325.htm#5">

  <p>To ask the Scottish Executive which local regeneration projects will transfer from being the responsibility of Scottish Enterprise and Highlands and Islands Enterprise to that of local authorities, broken down by local authority.</p>

</ques>


<ques id="uk.org.publicwhip/spwa/2008-03-25.S3W-10892.q2" speakerid="uk.org.publicwhip/member/80369" speakername="Elaine Murray (Dumfries) (Lab)" spid="S3W-10892" url="http://www.scottish.parliament.uk/business/pqa/wa-08/wa0325.htm#5">

  <p>To ask the Scottish Executive which regional regeneration projects will become the responsibility of the Scottish Enterprise regional networks after 1 April 2008.</p>

</ques>


<reply id="uk.org.publicwhip/spwa/2008-03-25.S3W-10892.r0" speakerid="uk.org.publicwhip/member/80347" speakername="Jim Mather" url="http://www.scottish.parliament.uk/business/pqa/wa-08/wa0325.htm#5">

  <p>These matters are under discussion with the Convention of Scottish Local Authorities.</p>

</reply>


<minor-heading id="uk.org.publicwhip/spwa/2008-03-25.S3W-10893.h" nospeaker="True" url="http://www.scottish.parliament.uk/business/pqa/wa-08/wa0325.htm#5">Enterprise</minor-heading>

<ques id="uk.org.publicwhip/spwa/2008-03-25.S3W-10893.q0" speakerid="uk.org.publicwhip/member/80369" speakername="Elaine Murray (Dumfries) (Lab)" spid="S3W-10893" url="http://www.scottish.parliament.uk/business/pqa/wa-08/wa0325.htm#5">

  <p>To ask the Scottish Executive which regeneration projects have been assessed as being of national importance and will remain the responsibility of Scottish Enterprise and Highlands and Islands Enterprise after 1 April 2008.</p>

</ques>


<reply id="uk.org.publicwhip/spwa/2008-03-25.S3W-10893.r0" speakerid="uk.org.publicwhip/member/80347" speakername="Jim Mather" url="http://www.scottish.parliament.uk/business/pqa/wa-08/wa0325.htm#5">

  <p>The transfer of responsibility for local regeneration projects to local authorities is under discussion with the Convention of Scottish Local Authorities. Once this process is concluded, appropriate details will be made public.</p>

</reply>


<minor-heading id="uk.org.publicwhip/spwa/2008-03-25.S3W-10780.h" nospeaker="True" url="http://www.scottish.parliament.uk/business/pqa/wa-08/wa0325.htm#6">Ferry Services</minor-heading>

<ques id="uk.org.publicwhip/spwa/2008-03-25.S3W-10780.q0" speakerid="uk.org.publicwhip/member/80378" speakername="Jeremy Purvis (Tweeddale, Ettrick and Lauderdale) (LD)" spid="S3W-10780" url="http://www.scottish.parliament.uk/business/pqa/wa-08/wa0325.htm#6">

  <p>To ask the Scottish Executive how much capital funding from the Scottish budget will be invested in the construction of the Borders rail project.</p>

</ques>


<reply id="uk.org.publicwhip/spwa/2008-03-25.S3W-10780.r0" speakerid="uk.org.publicwhip/member/80393" speakername="Stewart Stevenson" url="http://www.scottish.parliament.uk/business/pqa/wa-08/wa0325.htm#6">

  <p>Exact details of how much capital funding from the Scottish budget will be invested in the construction of the Borders rail project will be the subject of negotiations with the successful tenderer but is expected to be between the range of &pound;235 million and &pound;295 million as answered in my statement to Parliament on 5 March 2008.</p>

</reply>


<minor-heading id="uk.org.publicwhip/spwa/2008-03-25.S3W-10829.h" nospeaker="True" url="http://www.scottish.parliament.uk/business/pqa/wa-08/wa0325.htm#6">Ferry Services</minor-heading>

<ques id="uk.org.publicwhip/spwa/2008-03-25.S3W-10829.q0" speakerid="uk.org.publicwhip/member/80363" speakername="Des McNulty (Clydebank and Milngavie) (Lab)" spid="S3W-10829" url="http://www.scottish.parliament.uk/business/pqa/wa-08/wa0325.htm#6">

  <p>To ask the Scottish Executive what plans it has to reduce ferry fares on CalMac&rsquo;s Clyde routes from Ardrossan to Brodick and Largs to Cumbrae for (a) foot passenger, (b) vehicle and driver and (c) freight transport.</p>

</ques>


<ques id="uk.org.publicwhip/spwa/2008-03-25.S3W-10830.q1" speakerid="uk.org.publicwhip/member/80363" speakername="Des McNulty (Clydebank and Milngavie) (Lab)" spid="S3W-10830" url="http://www.scottish.parliament.uk/business/pqa/wa-08/wa0325.htm#6">

  <p>To ask the Scottish Executive when road equivalent tariff will be introduced on CalMac&rsquo;s Clyde routes from Ardrossan to Brodick and Largs to Cumbrae.</p>

</ques>


<ques id="uk.org.publicwhip/spwa/2008-03-25.S3W-10832.q2" speakerid="uk.org.publicwhip/member/80363" speakername="Des McNulty (Clydebank and Milngavie) (Lab)" spid="S3W-10832" url="http://www.scottish.parliament.uk/business/pqa/wa-08/wa0325.htm#6">

  <p>To ask the Scottish Executive whether it considers that the fares charged by CalMac for travel between Brodick to Ardrossan and between Cumbrae to Largs are fair.</p>

</ques>


<ques id="uk.org.publicwhip/spwa/2008-03-25.S3W-10833.q3" speakerid="uk.org.publicwhip/member/80363" speakername="Des McNulty (Clydebank and Milngavie) (Lab)" spid="S3W-10833" url="http://www.scottish.parliament.uk/business/pqa/wa-08/wa0325.htm#6">

  <p>To ask the Scottish Executive whether it considers it discriminatory that ferry fares on the Largs to Cumbrae route and Ardrossan to Brodick routes remain at current levels when the Scottish Government proposes to reduce fares and increase the public subsidy paid to CalMac to operate certain routes to the Western Isles via a pilot road equivalent tariff scheme.</p>

</ques>


<ques id="uk.org.publicwhip/spwa/2008-03-25.S3W-10835.q4" speakerid="uk.org.publicwhip/member/80363" speakername="Des McNulty (Clydebank and Milngavie) (Lab)" spid="S3W-10835" url="http://www.scottish.parliament.uk/business/pqa/wa-08/wa0325.htm#6">

  <p>To ask the Scottish Executive whether it will consider a 40% reduction in ferry fares for residents of the Isles of Arran and Cumbrae on the Clyde and what the reasons are for its position.</p>

</ques>


<reply id="uk.org.publicwhip/spwa/2008-03-25.S3W-10835.r0" speakerid="uk.org.publicwhip/member/80393" speakername="Stewart Stevenson" url="http://www.scottish.parliament.uk/business/pqa/wa-08/wa0325.htm#6">

  <p>The Scottish Government understand the genuine concerns from our remote and fragile communities about the affordability of ferry travel and the impact that has on island economies. That is why we are investigating road equivalent tariff as the basis for ferry fares in Scotland.</p>

  <p>That investigation includes a pilot study focussing on the Western Isles. By the very nature of a pilot study it is not possible to include all routes, however the pilot will inform the possible future roll out of the scheme across the rest of the Clyde and Hebrides and Northern Isles networks.</p>

</reply>


<minor-heading id="uk.org.publicwhip/spwa/2008-03-25.S3W-10831.h" nospeaker="True" url="http://www.scottish.parliament.uk/business/pqa/wa-08/wa0325.htm#6">Ferry Services</minor-heading>

<ques id="uk.org.publicwhip/spwa/2008-03-25.S3W-10831.q0" speakerid="uk.org.publicwhip/member/80363" speakername="Des McNulty (Clydebank and Milngavie) (Lab)" spid="S3W-10831" url="http://www.scottish.parliament.uk/business/pqa/wa-08/wa0325.htm#6">

  <p>To ask the Scottish Executive whether it supports the subsidisation of other CalMac routes by revenues from the fares charged on the CalMac ferry routes from Ardrossan to Brodick and Largs to Cumbrae.</p>

</ques>


<reply id="uk.org.publicwhip/spwa/2008-03-25.S3W-10831.r0" speakerid="uk.org.publicwhip/member/80393" speakername="Stewart Stevenson" url="http://www.scottish.parliament.uk/business/pqa/wa-08/wa0325.htm#6">

  <p>The Clyde and Hebrides ferry services (CHFS) are almost wholly funded by a mix of fares revenue and Scottish Government grant support through the Public Service Contract. The reduction in fares revenue on the road equivalent tariff (RET) pilot routes will be covered by additional grant support from the Scottish Government. Consequently, the introduction of RET will have no impact on the fares, and available discounts on fares, on the other routes.</p>

</reply>


<minor-heading id="uk.org.publicwhip/spwa/2008-03-25.S3W-10834.h" nospeaker="True" url="http://www.scottish.parliament.uk/business/pqa/wa-08/wa0325.htm#6">Ferry Services</minor-heading>

<ques id="uk.org.publicwhip/spwa/2008-03-25.S3W-10834.q0" speakerid="uk.org.publicwhip/member/80363" speakername="Des McNulty (Clydebank and Milngavie) (Lab)" spid="S3W-10834" url="http://www.scottish.parliament.uk/business/pqa/wa-08/wa0325.htm#6">

  <p>To ask the Scottish Executive what equivalent fares are charged by CalMac per mile, or part thereof, on each of its routes, for (a) foot passenger, (b) vehicle and driver and (c) freight transport.</p>

</ques>


<reply id="uk.org.publicwhip/spwa/2008-03-25.S3W-10834.r0" speakerid="uk.org.publicwhip/member/80393" speakername="Stewart Stevenson" url="http://www.scottish.parliament.uk/business/pqa/wa-08/wa0325.htm#6">

  <p>The consultants are finalising the first phase of the study into road equivalent tariff (RET). The report will include details of current fares and potential RET fares for all ferry services subsidised by the Scottish Government.</p>

  <p>I will ensure that you are sent a final copy of the report when it is available.</p>

</reply>


<minor-heading id="uk.org.publicwhip/spwa/2008-03-25.S3W-10914.h" nospeaker="True" url="http://www.scottish.parliament.uk/business/pqa/wa-08/wa0325.htm#6">Ferry Services</minor-heading>

<ques id="uk.org.publicwhip/spwa/2008-03-25.S3W-10914.q0" speakerid="uk.org.publicwhip/member/80354" speakername="Jamie McGrigor (Highlands and Islands) (Con)" spid="S3W-10914" url="http://www.scottish.parliament.uk/business/pqa/wa-08/wa0325.htm#6">

  <p>To ask the Scottish Executive what discussions it has had with the European Commission about the road equivalent tariff pilot scheme.</p>

</ques>


<ques id="uk.org.publicwhip/spwa/2008-03-25.S3W-10915.q1" speakerid="uk.org.publicwhip/member/80354" speakername="Jamie McGrigor (Highlands and Islands) (Con)" spid="S3W-10915" url="http://www.scottish.parliament.uk/business/pqa/wa-08/wa0325.htm#6">

  <p>To ask the Scottish Executive what information it has on whether the European Commission considers that the road equivalent tariff pilot scheme conforms to all the regulations contained in the European state aid and maritime cabotage legislation.</p>

</ques>


<reply id="uk.org.publicwhip/spwa/2008-03-25.S3W-10915.r0" speakerid="uk.org.publicwhip/member/80393" speakername="Stewart Stevenson" url="http://www.scottish.parliament.uk/business/pqa/wa-08/wa0325.htm#6">

  <p>To date the Scottish Government has had no discussions with the European Commission about the road equivalent tariff (RET) study. However, we will provide the European Commission with information on the pilot study once details have been finalised.</p>

</reply>


<minor-heading id="uk.org.publicwhip/spwa/2008-03-25.S3W-10916.h" nospeaker="True" url="http://www.scottish.parliament.uk/business/pqa/wa-08/wa0325.htm#6">Ferry Services</minor-heading>

<ques id="uk.org.publicwhip/spwa/2008-03-25.S3W-10916.q0" speakerid="uk.org.publicwhip/member/80354" speakername="Jamie McGrigor (Highlands and Islands) (Con)" spid="S3W-10916" url="http://www.scottish.parliament.uk/business/pqa/wa-08/wa0325.htm#6">

  <p>To ask the Scottish Executive whether the additional subsidy payments specifically associated with road equivalent tariff discounts are payable to other ferry operators if they operate in competition with CalMac&rsquo;s routes.</p>

</ques>


<reply id="uk.org.publicwhip/spwa/2008-03-25.S3W-10916.r0" speakerid="uk.org.publicwhip/member/80393" speakername="Stewart Stevenson" url="http://www.scottish.parliament.uk/business/pqa/wa-08/wa0325.htm#6">

  <p>The road equivalent tariff (RET) pilot study focuses on routes subsidised by the Scottish Government. In developing proposals for the possible roll out of RET across the Clyde and Hebrides and Northern Isles networks consideration will be given to ferry services provided by operators other than CalMac Ferries Limited.</p>

</reply>


<minor-heading id="uk.org.publicwhip/spwa/2008-03-25.S3W-10917.h" nospeaker="True" url="http://www.scottish.parliament.uk/business/pqa/wa-08/wa0325.htm#6">Ferry Services</minor-heading>

<ques id="uk.org.publicwhip/spwa/2008-03-25.S3W-10917.q0" speakerid="uk.org.publicwhip/member/80354" speakername="Jamie McGrigor (Highlands and Islands) (Con)" spid="S3W-10917" url="http://www.scottish.parliament.uk/business/pqa/wa-08/wa0325.htm#6">

  <p>To ask the Scottish Executive whether the road equivalent tariff (RET) pilot scheme will consider whether RET will have a positive or negative effect on current and potential competition on ferry routes.</p>

</ques>


<reply id="uk.org.publicwhip/spwa/2008-03-25.S3W-10917.r0" speakerid="uk.org.publicwhip/member/80393" speakername="Stewart Stevenson" url="http://www.scottish.parliament.uk/business/pqa/wa-08/wa0325.htm#6">

  <p>The examination and assessment of the impact of introduction of the road equivalent tariff approach is the principal reason why we are carrying out a pilot. While the desk-based study has been very informative only a live pilot can determine what the impact of a road equivalent tariff scheme will be, not just on the pilot routes but elsewhere in the Clyde and Hebrides and Northern Isles networks. That assessment will be comprehensive and consider usage and revenue impacts as well as economic and social impacts.</p>

  <p>The pilot scheme will be closely monitored to capture all the information required to inform future decisions on fare levels across the entire Scottish ferry network.</p>

</reply>


<minor-heading id="uk.org.publicwhip/spwa/2008-03-25.S3W-11051.h" nospeaker="True" url="http://www.scottish.parliament.uk/business/pqa/wa-08/wa0325.htm#7">Health</minor-heading>

<ques id="uk.org.publicwhip/spwa/2008-03-25.S3W-11051.q0" speakerid="uk.org.publicwhip/member/80315" speakername="Kenneth Gibson (Cunninghame North) (SNP)" spid="S3W-11051" url="http://www.scottish.parliament.uk/business/pqa/wa-08/wa0325.htm#7">

  <p>To ask the Scottish Executive what percentage of women have had smear tests in each of the last five years for which figures are available, broken down by NHS board.</p>

</ques>


<reply id="uk.org.publicwhip/spwa/2008-03-25.S3W-11051.r0" speakerid="uk.org.publicwhip/member/80379" speakername="Shona Robison" url="http://www.scottish.parliament.uk/business/pqa/wa-08/wa0325.htm#7">

  <p>The information requested is given on the Information Services Division Website at:</p>

  <p><a href="http://www.isdscotland.org/isd/servlet/FileBuffer?namedFile=Cervical_cancer_screening_annual_statistics.xls&amp;pContentDispositionType=inline" target="_blank">http://www.isdscotland.org/isd/servlet/FileBuffer?namedFile=Cervical_cancer_screening_annual_statistics.xls&amp;pContentDispositionType=inline</a>.</p>

</reply>


<minor-heading id="uk.org.publicwhip/spwa/2008-03-25.S3W-10903.h" nospeaker="True" url="http://www.scottish.parliament.uk/business/pqa/wa-08/wa0325.htm#8">Justice</minor-heading>

<ques id="uk.org.publicwhip/spwa/2008-03-25.S3W-10903.q0" speakerid="uk.org.publicwhip/member/80336" speakername="Bill Kidd (Glasgow) (SNP)" spid="S3W-10903" url="http://www.scottish.parliament.uk/business/pqa/wa-08/wa0325.htm#8">

  <p>To ask the Scottish Executive which organisations will receive funding from the &pound;200,000 to tackle gang culture, announced on 14 February 2008.</p>

</ques>


<ques id="uk.org.publicwhip/spwa/2008-03-25.S3W-10904.q1" speakerid="uk.org.publicwhip/member/80336" speakername="Bill Kidd (Glasgow) (SNP)" spid="S3W-10904" url="http://www.scottish.parliament.uk/business/pqa/wa-08/wa0325.htm#8">

  <p>To ask the Scottish Executive how organisations should bid for funding from the &pound;200,000 to tackle gang culture, announced on 14 February 2008.</p>

</ques>


<ques id="uk.org.publicwhip/spwa/2008-03-25.S3W-10905.q2" speakerid="uk.org.publicwhip/member/80336" speakername="Bill Kidd (Glasgow) (SNP)" spid="S3W-10905" url="http://www.scottish.parliament.uk/business/pqa/wa-08/wa0325.htm#8">

  <p>To ask the Scottish Executive when the bidding process for funding from the &pound;200,000 to tackle gang culture, announced on 14 February 2008, will close.</p>

</ques>


<ques id="uk.org.publicwhip/spwa/2008-03-25.S3W-10906.q3" speakerid="uk.org.publicwhip/member/80336" speakername="Bill Kidd (Glasgow) (SNP)" spid="S3W-10906" url="http://www.scottish.parliament.uk/business/pqa/wa-08/wa0325.htm#8">

  <p>To ask the Scottish Executive which professionals will receive special training and toolkits as a result of the &pound;200,000 funding to tackle gang culture, announced on 14 February 2008.</p>

</ques>


<reply id="uk.org.publicwhip/spwa/2008-03-25.S3W-10906.r0" speakerid="uk.org.publicwhip/member/80306" speakername="Fergus Ewing" url="http://www.scottish.parliament.uk/business/pqa/wa-08/wa0325.htm#8">

  <p>The closing date for applications for a share of the &pound;200,000 was 7 March 2008. Thirty bids from a range of statutory and voluntary organisations have been received and are currently being evaluated. All of the successful bids will deliver a range of educational, diversionary and behaviour change activities aimed at tackling gang and group violence and disorder within local communities. To support this work, 72 individuals from the police and local authorities across Scotland have been given specialist conflict resolution training and a supporting good practice toolkit to utilise during the initiative.</p>

</reply>


<minor-heading id="uk.org.publicwhip/spwa/2008-03-25.S3W-10887.h" nospeaker="True" url="http://www.scottish.parliament.uk/business/pqa/wa-08/wa0325.htm#9">Local Government Funding</minor-heading>

<ques id="uk.org.publicwhip/spwa/2008-03-25.S3W-10887.q0" speakerid="uk.org.publicwhip/member/80369" speakername="Elaine Murray (Dumfries) (Lab)" spid="S3W-10887" url="http://www.scottish.parliament.uk/business/pqa/wa-08/wa0325.htm#9">

  <p>To ask the Scottish Executive, further to the answer to question S3W-8170 by Jim Mather on 17 January 2008, whether the exact nature of the responsibilities to be transferred from Scottish Enterprise and Highlands and Islands Enterprise to local authorities as a consequence of its review of the structures and functions of the enterprise networks has now been determined and, if so, what those responsibilities are.</p>

</ques>


<reply id="uk.org.publicwhip/spwa/2008-03-25.S3W-10887.r0" speakerid="uk.org.publicwhip/member/80347" speakername="Jim Mather" url="http://www.scottish.parliament.uk/business/pqa/wa-08/wa0325.htm#9">

  <p>The details of the transfer of these functions are still under discussion with the Convention of Scottish Local Authorities. I expect this process to be concluded very shortly and intend that the details should be announced thereafter.</p>

</reply>


<minor-heading id="uk.org.publicwhip/spwa/2008-03-25.S3W-10888.h" nospeaker="True" url="http://www.scottish.parliament.uk/business/pqa/wa-08/wa0325.htm#9">Local Government Funding</minor-heading>

<ques id="uk.org.publicwhip/spwa/2008-03-25.S3W-10888.q0" speakerid="uk.org.publicwhip/member/80369" speakername="Elaine Murray (Dumfries) (Lab)" spid="S3W-10888" url="http://www.scottish.parliament.uk/business/pqa/wa-08/wa0325.htm#9">

  <p>To ask the Scottish Executive what funding will be made available to each local authority in each of the next three financial years to support the responsibilities transferred from Scottish Enterprise and Highlands and Islands Enterprise to support Business Gateway.</p>

</ques>


<reply id="uk.org.publicwhip/spwa/2008-03-25.S3W-10888.r0" speakerid="uk.org.publicwhip/member/80347" speakername="Jim Mather" url="http://www.scottish.parliament.uk/business/pqa/wa-08/wa0325.htm#9">

  <p>Details of the transfer of responsibility for delivery of the Business Gateway, including the associated funding resources, are still under discussion with the Convention of Scottish Local Authorities. I expect this process to be concluded very shortly and intend that the details should be announced thereafter.</p>

</reply>


<minor-heading id="uk.org.publicwhip/spwa/2008-03-25.S3W-10836.h" nospeaker="True" url="http://www.scottish.parliament.uk/business/pqa/wa-08/wa0325.htm#10">Medication</minor-heading>

<ques id="uk.org.publicwhip/spwa/2008-03-25.S3W-10836.q0" speakerid="uk.org.publicwhip/member/80395" speakername="Jamie Stone (Caithness, Sutherland and Easter Ross) (LD)" spid="S3W-10836" url="http://www.scottish.parliament.uk/business/pqa/wa-08/wa0325.htm#10">

  <p>To ask the Scottish Executive how many prescriptions were issued for benzodiazepines in each of the last 10 years and what the total cost was to the NHS in each year, broken down by all available drugs.</p>

</ques>


<reply id="uk.org.publicwhip/spwa/2008-03-25.S3W-10836.r0" speakerid="uk.org.publicwhip/member/80379" speakername="Shona Robison" url="http://www.scottish.parliament.uk/business/pqa/wa-08/wa0325.htm#10">

  <p>The following tables show the number of prescribed items and gross ingredient cost for benzodiazepines for the financial years ending 31 March 1998 to 2007. The data given refer to prescriptions dispensed in the community by community pharmacists and dispensing doctors but do not include medicines dispensed by hospitals or hospital-based clinics. The cost given is that before addition of any pharmacy fees and deduction of any discount and patient charges.</p>

  <p>Number of Prescribed Items</p>

  <p><table width="75%" border="BORDER" cellpadding="2" cellspacing="0" bordercolor="#CCCCCC">
<tr>
<td width="30%" align="left" valign="top"> Year ended 31 March</td>
<td width="14%" align="center" valign="top"> 1998</td>
<td width="14%" align="center" valign="top"> 1999</td>
<td width="14%" align="center" valign="top"> 2000</td>
<td width="14%" align="center" valign="top"> 2001</td>
<td width="14%" align="center" valign="top"> 2002</td>
</tr>
<tr>
<td width="30%" align="left" valign="top"> Buspirone Hydrochloride</td>
<td width="14%" align="right" valign="top"> 18,422</td>
<td width="14%" align="right" valign="top"> 19,020</td>
<td width="14%" align="right" valign="top"> 17,599</td>
<td width="14%" align="right" valign="top"> 18,303</td>
<td width="14%" align="right" valign="top"> 19,802</td>
</tr>
<tr>
<td width="30%" align="left" valign="top"> Chlordiazepoxide</td>
<td width="14%" align="right" valign="top"> 103,677</td>
<td width="14%" align="right" valign="top"> 100,113</td>
<td width="14%" align="right" valign="top"> 95,274</td>
<td width="14%" align="right" valign="top"> 90,629</td>
<td width="14%" align="right" valign="top"> 88,286</td>
</tr>
<tr>
<td width="30%" align="left" valign="top"> Diazepam</td>
<td width="14%" align="right" valign="top"> 647,193</td>
<td width="14%" align="right" valign="top"> 670,641</td>
<td width="14%" align="right" valign="top"> 680,770</td>
<td width="14%" align="right" valign="top"> 704,114</td>
<td width="14%" align="right" valign="top"> 737,429</td>
</tr>
<tr>
<td width="30%" align="left" valign="top"> Loprazolam</td>
<td width="14%" align="right" valign="top"> 48,845</td>
<td width="14%" align="right" valign="top"> 46,923</td>
<td width="14%" align="right" valign="top"> 46,711</td>
<td width="14%" align="right" valign="top"> 46,469</td>
<td width="14%" align="right" valign="top"> 44,038</td>
</tr>
<tr>
<td width="30%" align="left" valign="top"> Lorazepam</td>
<td width="14%" align="right" valign="top"> 72,213</td>
<td width="14%" align="right" valign="top"> 69,326</td>
<td width="14%" align="right" valign="top"> 65,162</td>
<td width="14%" align="right" valign="top"> 62,855</td>
<td width="14%" align="right" valign="top"> 63,824</td>
</tr>
<tr>
<td width="30%" align="left" valign="top"> Lormetazepam</td>
<td width="14%" align="right" valign="top"> 58,850</td>
<td width="14%" align="right" valign="top"> 60,709</td>
<td width="14%" align="right" valign="top"> 59,918</td>
<td width="14%" align="right" valign="top"> 51,790</td>
<td width="14%" align="right" valign="top"> 52,053</td>
</tr>
<tr>
<td width="30%" align="left" valign="top"> Nitrazepam</td>
<td width="14%" align="right" valign="top"> 288,512</td>
<td width="14%" align="right" valign="top"> 273,927</td>
<td width="14%" align="right" valign="top"> 258,282</td>
<td width="14%" align="right" valign="top"> 245,181</td>
<td width="14%" align="right" valign="top"> 231,777</td>
</tr>
<tr>
<td width="30%" align="left" valign="top"> Oxazepam</td>
<td width="14%" align="right" valign="top"> 29,890</td>
<td width="14%" align="right" valign="top"> 29,303</td>
<td width="14%" align="right" valign="top"> 27,522</td>
<td width="14%" align="right" valign="top"> 25,105</td>
<td width="14%" align="right" valign="top"> 24,312</td>
</tr>
<tr>
<td width="30%" align="left" valign="top"> Temazepam</td>
<td width="14%" align="right" valign="top"> 584,122</td>
<td width="14%" align="right" valign="top"> 548,001</td>
<td width="14%" align="right" valign="top"> 517,397</td>
<td width="14%" align="right" valign="top"> 481,836</td>
<td width="14%" align="right" valign="top"> 455,416</td>
</tr>
<tr>
<td width="30%" align="left" valign="top"> Total</td>
<td width="14%" align="right" valign="top"> 1,851,724</td>
<td width="14%" align="right" valign="top"> 1,817,963</td>
<td width="14%" align="right" valign="top"> 1,768,635</td>
<td width="14%" align="right" valign="top"> 1,726,282</td>
<td width="14%" align="right" valign="top"> 1,716,937</td>
</tr>
</table></p>

  <p>Number of Prescribed Items (Continued)</p>

  <p><table width="75%" border="BORDER" cellpadding="2" cellspacing="0" bordercolor="#CCCCCC">
<tr>
<td width="30%" align="left" valign="top"> Year ended 31 March</td>
<td width="15%" align="center" valign="top"> 2003</td>
<td width="14%" align="center" valign="top"> 2004</td>
<td width="14%" align="center" valign="top"> 2005</td>
<td width="14%" align="center" valign="top"> 2006</td>
<td width="14%" align="center" valign="top"> 2007</td>
</tr>
<tr>
<td width="30%" align="left" valign="top"> Buspirone Hydrochloride</td>
<td width="15%" align="right" valign="top"> 20,756</td>
<td width="14%" align="right" valign="top"> 21,751</td>
<td width="14%" align="right" valign="top"> 22,014</td>
<td width="14%" align="right" valign="top"> 22,372</td>
<td width="14%" align="right" valign="top"> 22,190</td>
</tr>
<tr>
<td width="30%" align="left" valign="top"> Chlordiazepoxide</td>
<td width="15%" align="right" valign="top"> 84,801</td>
<td width="14%" align="right" valign="top"> 81,359</td>
<td width="14%" align="right" valign="top"> 78,180</td>
<td width="14%" align="right" valign="top"> 73,999</td>
<td width="14%" align="right" valign="top"> 71,332</td>
</tr>
<tr>
<td width="30%" align="left" valign="top"> Diazepam</td>
<td width="15%" align="right" valign="top"> 757,251</td>
<td width="14%" align="right" valign="top"> 779,249</td>
<td width="14%" align="right" valign="top"> 791,309</td>
<td width="14%" align="right" valign="top"> 812,299</td>
<td width="14%" align="right" valign="top"> 833,933</td>
</tr>
<tr>
<td width="30%" align="left" valign="top"> Loprazolam</td>
<td width="15%" align="right" valign="top"> 41,036</td>
<td width="14%" align="right" valign="top"> 37,069</td>
<td width="14%" align="right" valign="top"> 33,112</td>
<td width="14%" align="right" valign="top"> 28,357</td>
<td width="14%" align="right" valign="top"> 26,098</td>
</tr>
<tr>
<td width="30%" align="left" valign="top"> Lorazepam</td>
<td width="15%" align="right" valign="top"> 65,215</td>
<td width="14%" align="right" valign="top"> 66,415</td>
<td width="14%" align="right" valign="top"> 69,450</td>
<td width="14%" align="right" valign="top"> 73,681</td>
<td width="14%" align="right" valign="top"> 77,699</td>
</tr>
<tr>
<td width="30%" align="left" valign="top"> Lormetazepam</td>
<td width="15%" align="right" valign="top"> 51,682</td>
<td width="14%" align="right" valign="top"> 49,170</td>
<td width="14%" align="right" valign="top"> 49,367</td>
<td width="14%" align="right" valign="top"> 47,935</td>
<td width="14%" align="right" valign="top"> 47,605</td>
</tr>
<tr>
<td width="30%" align="left" valign="top"> Nitrazepam</td>
<td width="15%" align="right" valign="top"> 219,797</td>
<td width="14%" align="right" valign="top"> 207,423</td>
<td width="14%" align="right" valign="top"> 195,170</td>
<td width="14%" align="right" valign="top"> 185,171</td>
<td width="14%" align="right" valign="top"> 177,457</td>
</tr>
<tr>
<td width="30%" align="left" valign="top"> Oxazepam</td>
<td width="15%" align="right" valign="top"> 23,081</td>
<td width="14%" align="right" valign="top"> 22,105</td>
<td width="14%" align="right" valign="top"> 20,846</td>
<td width="14%" align="right" valign="top"> 19,931</td>
<td width="14%" align="right" valign="top"> 19,660</td>
</tr>
<tr>
<td width="30%" align="left" valign="top"> Temazepam</td>
<td width="15%" align="right" valign="top"> 433,130</td>
<td width="14%" align="right" valign="top"> 412,417</td>
<td width="14%" align="right" valign="top"> 392,512</td>
<td width="14%" align="right" valign="top"> 376,364</td>
<td width="14%" align="right" valign="top"> 367,177</td>
</tr>
<tr>
<td width="30%" align="left" valign="top"> Total</td>
<td width="15%" align="right" valign="top"> 1,696,749</td>
<td width="14%" align="right" valign="top"> 1,676,958</td>
<td width="14%" align="right" valign="top"> 1,651,960</td>
<td width="14%" align="right" valign="top"> 1,640,109</td>
<td width="14%" align="right" valign="top"> 1,643,151</td>
</tr>
</table></p>

  <p>Gross Ingredient Cost (&pound;)</p>

  <p><table width="75%" border="BORDER" cellpadding="2" cellspacing="0" bordercolor="#CCCCCC">
<tr>
<td width="31%" align="left" valign="top"> Year ended 31 March</td>
<td width="14%" align="center" valign="top"> 1998</td>
<td width="14%" align="center" valign="top"> 1999</td>
<td width="14%" align="center" valign="top"> 2000</td>
<td width="14%" align="center" valign="top"> 2001</td>
<td width="14%" align="center" valign="top"> 2002</td>
</tr>
<tr>
<td width="31%" align="left" valign="top"> Buspirone Hydrochloride</td>
<td width="14%" align="right" valign="top"> 399,199</td>
<td width="14%" align="right" valign="top"> 423,441</td>
<td width="14%" align="right" valign="top"> 397,898</td>
<td width="14%" align="right" valign="top"> 413,498</td>
<td width="14%" align="right" valign="top"> 455,239</td>
</tr>
<tr>
<td width="31%" align="left" valign="top"> Chlordiazepoxide</td>
<td width="14%" align="right" valign="top"> 78,258</td>
<td width="14%" align="right" valign="top"> 86,533</td>
<td width="14%" align="right" valign="top"> 248,744</td>
<td width="14%" align="right" valign="top"> 237,337</td>
<td width="14%" align="right" valign="top"> 230,444</td>
</tr>
<tr>
<td width="31%" align="left" valign="top"> Diazepam</td>
<td width="14%" align="right" valign="top"> 252,930</td>
<td width="14%" align="right" valign="top"> 279,044</td>
<td width="14%" align="right" valign="top"> 695,635</td>
<td width="14%" align="right" valign="top"> 1,078,186</td>
<td width="14%" align="right" valign="top"> 958,853</td>
</tr>
<tr>
<td width="31%" align="left" valign="top"> Loprazolam</td>
<td width="14%" align="right" valign="top"> 197,907</td>
<td width="14%" align="right" valign="top"> 268,918</td>
<td width="14%" align="right" valign="top"> 295,028</td>
<td width="14%" align="right" valign="top"> 265,550</td>
<td width="14%" align="right" valign="top"> 251,574</td>
</tr>
<tr>
<td width="31%" align="left" valign="top"> Lorazepam</td>
<td width="14%" align="right" valign="top"> 50,805</td>
<td width="14%" align="right" valign="top"> 47,940</td>
<td width="14%" align="right" valign="top"> 54,968</td>
<td width="14%" align="right" valign="top"> 112,112</td>
<td width="14%" align="right" valign="top"> 148,732</td>
</tr>
<tr>
<td width="31%" align="left" valign="top"> Lormetazepam</td>
<td width="14%" align="right" valign="top"> 81,841</td>
<td width="14%" align="right" valign="top"> 83,106</td>
<td width="14%" align="right" valign="top"> 86,334</td>
<td width="14%" align="right" valign="top"> 142,617</td>
<td width="14%" align="right" valign="top"> 228,585</td>
</tr>
<tr>
<td width="31%" align="left" valign="top"> Nitrazepam</td>
<td width="14%" align="right" valign="top"> 135,235</td>
<td width="14%" align="right" valign="top"> 140,102</td>
<td width="14%" align="right" valign="top"> 455,560</td>
<td width="14%" align="right" valign="top"> 461,028</td>
<td width="14%" align="right" valign="top"> 351,268</td>
</tr>
<tr>
<td width="31%" align="left" valign="top"> Oxazepam</td>
<td width="14%" align="right" valign="top"> 20,510</td>
<td width="14%" align="right" valign="top"> 19,761</td>
<td width="14%" align="right" valign="top"> 22,290</td>
<td width="14%" align="right" valign="top"> 44,092</td>
<td width="14%" align="right" valign="top"> 55,067</td>
</tr>
<tr>
<td width="31%" align="left" valign="top"> Temazepam</td>
<td width="14%" align="right" valign="top"> 1,022,121</td>
<td width="14%" align="right" valign="top"> 965,009</td>
<td width="14%" align="right" valign="top"> 927,608</td>
<td width="14%" align="right" valign="top"> 851,460</td>
<td width="14%" align="right" valign="top"> 753,603</td>
</tr>
<tr>
<td width="31%" align="left" valign="top"> Total</td>
<td width="14%" align="right" valign="top"> 2,238,806</td>
<td width="14%" align="right" valign="top"> 2,313,854</td>
<td width="14%" align="right" valign="top"> 3,184,064</td>
<td width="14%" align="right" valign="top"> 3,605,882</td>
<td width="14%" align="right" valign="top"> 3,433,366</td>
</tr>
</table></p>

  <p>Gross Ingredient Cost (&pound;) (Continued)</p>

  <p><table width="75%" border="BORDER" cellpadding="2" cellspacing="0" bordercolor="#CCCCCC">
<tr>
<td width="30%" align="left" valign="top"> Year Ended 31 March</td>
<td width="15%" align="center" valign="top"> 2003</td>
<td width="14%" align="center" valign="top"> 2004</td>
<td width="14%" align="center" valign="top"> 2005</td>
<td width="14%" align="center" valign="top"> 2006</td>
<td width="14%" align="center" valign="top"> 2007</td>
</tr>
<tr>
<td width="30%" align="left" valign="top"> Buspirone Hydrochloride</td>
<td width="15%" align="right" valign="top"> 467,600</td>
<td width="14%" align="right" valign="top"> 477,113</td>
<td width="14%" align="right" valign="top"> 489,970</td>
<td width="14%" align="right" valign="top"> 717,699</td>
<td width="14%" align="right" valign="top"> 1,069,020</td>
</tr>
<tr>
<td width="30%" align="left" valign="top"> Chlordiazepoxide</td>
<td width="15%" align="right" valign="top"> 221,551</td>
<td width="14%" align="right" valign="top"> 213,026</td>
<td width="14%" align="right" valign="top"> 203,841</td>
<td width="14%" align="right" valign="top"> 222,808</td>
<td width="14%" align="right" valign="top"> 296,581</td>
</tr>
<tr>
<td width="30%" align="left" valign="top"> Diazepam</td>
<td width="15%" align="right" valign="top"> 925,724</td>
<td width="14%" align="right" valign="top"> 840,695</td>
<td width="14%" align="right" valign="top"> 844,871</td>
<td width="14%" align="right" valign="top"> 1,186,337</td>
<td width="14%" align="right" valign="top"> 2,257,269</td>
</tr>
<tr>
<td width="30%" align="left" valign="top"> Loprazolam</td>
<td width="15%" align="right" valign="top"> 236,572</td>
<td width="14%" align="right" valign="top"> 218,511</td>
<td width="14%" align="right" valign="top"> 195,069</td>
<td width="14%" align="right" valign="top"> 171,601</td>
<td width="14%" align="right" valign="top"> 177,123</td>
</tr>
<tr>
<td width="30%" align="left" valign="top"> Lorazepam</td>
<td width="15%" align="right" valign="top"> 160,688</td>
<td width="14%" align="right" valign="top"> 161,166</td>
<td width="14%" align="right" valign="top"> 160,721</td>
<td width="14%" align="right" valign="top"> 272,148</td>
<td width="14%" align="right" valign="top"> 755,113</td>
</tr>
<tr>
<td width="30%" align="left" valign="top"> Lormetazepam</td>
<td width="15%" align="right" valign="top"> 248,779</td>
<td width="14%" align="right" valign="top"> 239,456</td>
<td width="14%" align="right" valign="top"> 238,833</td>
<td width="14%" align="right" valign="top"> 390,429</td>
<td width="14%" align="right" valign="top"> 1,525,134</td>
</tr>
<tr>
<td width="30%" align="left" valign="top"> Nitrazepam</td>
<td width="15%" align="right" valign="top"> 308,668</td>
<td width="14%" align="right" valign="top"> 261,635</td>
<td width="14%" align="right" valign="top"> 244,572</td>
<td width="14%" align="right" valign="top"> 265,528</td>
<td width="14%" align="right" valign="top"> 417,157</td>
</tr>
<tr>
<td width="30%" align="left" valign="top"> Oxazepam</td>
<td width="15%" align="right" valign="top"> 53,761</td>
<td width="14%" align="right" valign="top"> 51,236</td>
<td width="14%" align="right" valign="top"> 47,257</td>
<td width="14%" align="right" valign="top"> 60,438</td>
<td width="14%" align="right" valign="top"> 131,244</td>
</tr>
<tr>
<td width="30%" align="left" valign="top"> Temazepam</td>
<td width="15%" align="right" valign="top"> 693,590</td>
<td width="14%" align="right" valign="top"> 657,513</td>
<td width="14%" align="right" valign="top"> 605,415</td>
<td width="14%" align="right" valign="top"> 562,558</td>
<td width="14%" align="right" valign="top"> 564,022</td>
</tr>
<tr>
<td width="30%" align="left" valign="top"> Total</td>
<td width="15%" align="right" valign="top"> 3,316,933</td>
<td width="14%" align="right" valign="top"> 3,120,350</td>
<td width="14%" align="right" valign="top"> 3,030,550</td>
<td width="14%" align="right" valign="top"> 3,849,546</td>
<td width="14%" align="right" valign="top"> 7,192,663</td>
</tr>
</table></p>

  <p>The information in the tables has been provided by NHS National Services Scotland.</p>

</reply>


<minor-heading id="uk.org.publicwhip/spwa/2008-03-25.S3W-10837.h" nospeaker="True" url="http://www.scottish.parliament.uk/business/pqa/wa-08/wa0325.htm#10">Medication</minor-heading>

<ques id="uk.org.publicwhip/spwa/2008-03-25.S3W-10837.q0" speakerid="uk.org.publicwhip/member/80395" speakername="Jamie Stone (Caithness, Sutherland and Easter Ross) (LD)" spid="S3W-10837" url="http://www.scottish.parliament.uk/business/pqa/wa-08/wa0325.htm#10">

  <p>To ask the Scottish Executive how many prescriptions were issued for Prozac in each of the last 10 years and what the total cost was to the NHS in each year.</p>

</ques>


<reply id="uk.org.publicwhip/spwa/2008-03-25.S3W-10837.r0" speakerid="uk.org.publicwhip/member/80379" speakername="Shona Robison" url="http://www.scottish.parliament.uk/business/pqa/wa-08/wa0325.htm#10">

  <p>The following table shows the number of prescribed items and gross ingredient cost for fluoxetine (Prozac) for the financial years ending 31 March 1998 to 2007. The data given refer to prescriptions dispensed in the community by community pharmacists and dispensing doctors but do not include medicines dispensed by hospitals or hospital-based clinics. The cost given is that before addition of any pharmacy fees and deduction of any discount and patient charges.</p>

  <p><table width="50%" border="BORDER" cellpadding="2" cellspacing="0" bordercolor="#CCCCCC">
<tr>
<td width="32%" align="left" valign="top"> Year Ended 31 March</td>
<td width="33%" align="center" valign="top"> No of Prescribed Items</td>
<td width="35%" align="center" valign="top"> Gross Ingredient Cost &pound;</td>
</tr>
<tr>
<td width="32%" align="left" valign="top"> 1998</td>
<td width="33%" align="right" valign="top"> 361,227</td>
<td width="35%" align="right" valign="top"> 9,586,678</td>
</tr>
<tr>
<td width="32%" align="left" valign="top"> 1999</td>
<td width="33%" align="right" valign="top"> 398,562</td>
<td width="35%" align="right" valign="top"> 10,729,594</td>
</tr>
<tr>
<td width="32%" align="left" valign="top"> 2000</td>
<td width="33%" align="right" valign="top"> 429,642</td>
<td width="35%" align="right" valign="top"> 11,335,969</td>
</tr>
<tr>
<td width="32%" align="left" valign="top"> 2001</td>
<td width="33%" align="right" valign="top"> 462,177</td>
<td width="35%" align="right" valign="top"> 6,145,791</td>
</tr>
<tr>
<td width="32%" align="left" valign="top"> 2002</td>
<td width="33%" align="right" valign="top"> 499,412</td>
<td width="35%" align="right" valign="top"> 4,626,659</td>
</tr>
<tr>
<td width="32%" align="left" valign="top"> 2003</td>
<td width="33%" align="right" valign="top"> 521,216</td>
<td width="35%" align="right" valign="top"> 4,538,107</td>
</tr>
<tr>
<td width="32%" align="left" valign="top"> 2004</td>
<td width="33%" align="right" valign="top"> 545,026</td>
<td width="35%" align="right" valign="top"> 3,661,045</td>
</tr>
<tr>
<td width="32%" align="left" valign="top"> 2005</td>
<td width="33%" align="right" valign="top"> 555,940</td>
<td width="35%" align="right" valign="top"> 2,304,228</td>
</tr>
<tr>
<td width="32%" align="left" valign="top"> 2006</td>
<td width="33%" align="right" valign="top"> 596,007</td>
<td width="35%" align="right" valign="top"> 2,350,272</td>
</tr>
<tr>
<td width="32%" align="left" valign="top"> 2007</td>
<td width="33%" align="right" valign="top"> 636,435</td>
<td width="35%" align="right" valign="top"> 3,166,666</td>
</tr>
</table></p>

  <p>The information in the table has been provided by NHS National Services Scotland.</p>

</reply>


<minor-heading id="uk.org.publicwhip/spwa/2008-03-25.S3W-10838.h" nospeaker="True" url="http://www.scottish.parliament.uk/business/pqa/wa-08/wa0325.htm#10">Medication</minor-heading>

<ques id="uk.org.publicwhip/spwa/2008-03-25.S3W-10838.q0" speakerid="uk.org.publicwhip/member/80395" speakername="Jamie Stone (Caithness, Sutherland and Easter Ross) (LD)" spid="S3W-10838" url="http://www.scottish.parliament.uk/business/pqa/wa-08/wa0325.htm#10">

  <p>To ask the Scottish Executive whether drug companies are required to provide all drug research information, published and unpublished, to the Scottish Medicines Consortium prior to obtaining a licence to have the drug distributed.</p>

</ques>


<ques id="uk.org.publicwhip/spwa/2008-03-25.S3W-10839.q1" speakerid="uk.org.publicwhip/member/80395" speakername="Jamie Stone (Caithness, Sutherland and Easter Ross) (LD)" spid="S3W-10839" url="http://www.scottish.parliament.uk/business/pqa/wa-08/wa0325.htm#10">

  <p>To ask the Scottish Executive whether drug companies have provided drug research to the Scottish Medicines Consortium at the time of licensing and, if not, how this affects the licensing process.</p>

</ques>


<reply id="uk.org.publicwhip/spwa/2008-03-25.S3W-10839.r0" speakerid="uk.org.publicwhip/member/80379" speakername="Shona Robison" url="http://www.scottish.parliament.uk/business/pqa/wa-08/wa0325.htm#10">

  <p>The licensing of medicines is reserved and is the responsibility of the Medicines and Healthcare products Regulatory Agency. The Scottish Medicines Consortium considers products after licensing. The information required from manufacturers is available from the Scottish Medicines Consortium&rsquo;s website <a href="http://www.scottishmedicines.org.uk/smc/CCC_FirstPage.jsp" target="_blank">http://www.scottishmedicines.org.uk/smc/CCC_FirstPage.jsp</a> .</p>

</reply>


<minor-heading id="uk.org.publicwhip/spwa/2008-03-25.S3W-10840.h" nospeaker="True" url="http://www.scottish.parliament.uk/business/pqa/wa-08/wa0325.htm#10">Medication</minor-heading>

<ques id="uk.org.publicwhip/spwa/2008-03-25.S3W-10840.q0" speakerid="uk.org.publicwhip/member/80395" speakername="Jamie Stone (Caithness, Sutherland and Easter Ross) (LD)" spid="S3W-10840" url="http://www.scottish.parliament.uk/business/pqa/wa-08/wa0325.htm#10">

  <p>To ask the Scottish Executive how many prescriptions have been issued for opiates, such as OxyContin and Percocet, since the drugs were made available through the NHS and what the total cost has been to the NHS each year, broken down by drug.</p>

</ques>


<reply id="uk.org.publicwhip/spwa/2008-03-25.S3W-10840.r0" speakerid="uk.org.publicwhip/member/80379" speakername="Shona Robison" url="http://www.scottish.parliament.uk/business/pqa/wa-08/wa0325.htm#10">

  <p>The following tables show the number of prescribed items and gross ingredient cost for opiates for the financial years ending 31 March 1993 to 2007. The data given refer to prescriptions dispensed in the community by community pharmacists and dispensing doctors but do not include medicines dispensed by hospitals or hospital-based clinics. The cost given is that before addition of any pharmacy fees and deduction of any discount and patient charges.</p>

  <p>Number of Prescribed Items</p>

  <p><table width="75%" border="BORDER" cellpadding="2" cellspacing="0" bordercolor="#CCCCCC">
<tr>
<td width="21%" align="left" valign="top"><p>Year Ended 31 March</p></td>
<td width="10%" align="center" valign="top"><p align="center">1993</p></td>
<td width="10%" align="center" valign="top"><p align="center">1994</p></td>
<td width="10%" align="center" valign="top"><p align="center">1995</p></td>
<td width="10%" align="center" valign="top"><p align="center">1996</p></td>
<td width="10%" align="center" valign="top"><p align="center">1997</p></td>
<td width="10%" align="center" valign="top"><p align="center">1998</p></td>
<td width="10%" align="center" valign="top"><p align="center">1999</p></td>
<td width="10%" align="center" valign="top"><p align="center">2000</p></td>
</tr>
<tr>
<td width="21%" align="left" valign="top"><p>Buprenorphine</p></td>
<td width="10%" align="right" valign="top"><p align="right">8,218</p></td>
<td width="10%" align="right" valign="top"><p align="right">28,817</p></td>
<td width="10%" align="right" valign="top"><p align="right">19,906</p></td>
<td width="10%" align="right" valign="top"><p align="right">14,717</p></td>
<td width="10%" align="right" valign="top"><p align="right">11,979</p></td>
<td width="10%" align="right" valign="top"><p align="right">9,974</p></td>
<td width="10%" align="right" valign="top"><p align="right">8,438</p></td>
<td width="10%" align="right" valign="top"><p align="right">7,359</p></td>
</tr>
<tr>
<td width="21%" align="left" valign="top"><p>Codeine Phosphate</p></td>
<td width="10%" align="right" valign="top"><p align="right">11,034</p></td>
<td width="10%" align="right" valign="top"><p align="right">46,735</p></td>
<td width="10%" align="right" valign="top"><p align="right">48,662</p></td>
<td width="10%" align="right" valign="top"><p align="right">50,513</p></td>
<td width="10%" align="right" valign="top"><p align="right">53,809</p></td>
<td width="10%" align="right" valign="top"><p align="right">55,611</p></td>
<td width="10%" align="right" valign="top"><p align="right">57,395</p></td>
<td width="10%" align="right" valign="top"><p align="right">57,310</p></td>
</tr>
<tr>
<td width="21%" align="left" valign="top"><p>Dextromoramide</p></td>
<td width="10%" align="right" valign="top"><p align="right">1,549</p></td>
<td width="10%" align="right" valign="top"><p align="right">6,797</p></td>
<td width="10%" align="right" valign="top"><p align="right">6,518</p></td>
<td width="10%" align="right" valign="top"><p align="right">5,864</p></td>
<td width="10%" align="right" valign="top"><p align="right">4,984</p></td>
<td width="10%" align="right" valign="top"><p align="right">5,054</p></td>
<td width="10%" align="right" valign="top"><p align="right">4,624</p></td>
<td width="10%" align="right" valign="top"><p align="right">3,936</p></td>
</tr>
<tr>
<td width="21%" align="left" valign="top"><p>Dextropropoxyphene Hydrochloride</p></td>
<td width="10%" align="right" valign="top"><p align="right">225</p></td>
<td width="10%" align="right" valign="top"><p align="right">871</p></td>
<td width="10%" align="right" valign="top"><p align="right">629</p></td>
<td width="10%" align="right" valign="top"><p align="right">598</p></td>
<td width="10%" align="right" valign="top"><p align="right">620</p></td>
<td width="10%" align="right" valign="top"><p align="right">531</p></td>
<td width="10%" align="right" valign="top"><p align="right">500</p></td>
<td width="10%" align="right" valign="top"><p align="right">480</p></td>
</tr>
<tr>
<td width="21%" align="left" valign="top"><p>Diamorphine Hydrochloride</p></td>
<td width="10%" align="right" valign="top"><p align="right">2,458</p></td>
<td width="10%" align="right" valign="top"><p align="right">10,043</p></td>
<td width="10%" align="right" valign="top"><p align="right">11,414</p></td>
<td width="10%" align="right" valign="top"><p align="right">10,705</p></td>
<td width="10%" align="right" valign="top"><p align="right">10,746</p></td>
<td width="10%" align="right" valign="top"><p align="right">11,510</p></td>
<td width="10%" align="right" valign="top"><p align="right">11,541</p></td>
<td width="10%" align="right" valign="top"><p align="right">11,338</p></td>
</tr>
<tr>
<td width="21%" align="left" valign="top"><p>Dihydrocodeine Tartrate</p></td>
<td width="10%" align="right" valign="top"><p align="right">80,089</p></td>
<td width="10%" align="right" valign="top"><p align="right">346,669</p></td>
<td width="10%" align="right" valign="top"><p align="right">358,454</p></td>
<td width="10%" align="right" valign="top"><p align="right">352,186</p></td>
<td width="10%" align="right" valign="top"><p align="right">370,623</p></td>
<td width="10%" align="right" valign="top"><p align="right">393,817</p></td>
<td width="10%" align="right" valign="top"><p align="right">417,445</p></td>
<td width="10%" align="right" valign="top"><p align="right">432,116</p></td>
</tr>
<tr>
<td width="21%" align="left" valign="top"><p>Dipipanone with Cyclizine</p></td>
<td width="10%" align="right" valign="top"><p align="right">2,941</p></td>
<td width="10%" align="right" valign="top"><p align="right">11,722</p></td>
<td width="10%" align="right" valign="top"><p align="right">11,549</p></td>
<td width="10%" align="right" valign="top"><p align="right">10,695</p></td>
<td width="10%" align="right" valign="top"><p align="right">10,174</p></td>
<td width="10%" align="right" valign="top"><p align="right">8,831</p></td>
<td width="10%" align="right" valign="top"><p align="right">8,145</p></td>
<td width="10%" align="right" valign="top"><p align="right">7,335</p></td>
</tr>
<tr>
<td width="21%" align="left" valign="top"><p>Fentanyl</p></td>
<td width="10%" align="right" valign="top"><p align="right">0</p></td>
<td width="10%" align="right" valign="top"><p align="right">0</p></td>
<td width="10%" align="right" valign="top"><p align="right">269</p></td>
<td width="10%" align="right" valign="top"><p align="right">3,562</p></td>
<td width="10%" align="right" valign="top"><p align="right">6,899</p></td>
<td width="10%" align="right" valign="top"><p align="right">8,677</p></td>
<td width="10%" align="right" valign="top"><p align="right">10,157</p></td>
<td width="10%" align="right" valign="top"><p align="right">11,467</p></td>
</tr>
<tr>
<td width="21%" align="left" valign="top"><p>Hydromorphone Hydrochloride</p></td>
<td width="10%" align="right" valign="top"><p align="right">0</p></td>
<td width="10%" align="right" valign="top"><p align="right">0</p></td>
<td width="10%" align="right" valign="top"><p align="right">0</p></td>
<td width="10%" align="right" valign="top"><p align="right">0</p></td>
<td width="10%" align="right" valign="top"><p align="right">0</p></td>
<td width="10%" align="right" valign="top"><p align="right">813</p></td>
<td width="10%" align="right" valign="top"><p align="right">2,604</p></td>
<td width="10%" align="right" valign="top"><p align="right">3,961</p></td>
</tr>
<tr>
<td width="21%" align="left" valign="top"><p>Meptazinol</p></td>
<td width="10%" align="right" valign="top"><p align="right">2,920</p></td>
<td width="10%" align="right" valign="top"><p align="right">13,305</p></td>
<td width="10%" align="right" valign="top"><p align="right">14,945</p></td>
<td width="10%" align="right" valign="top"><p align="right">15,613</p></td>
<td width="10%" align="right" valign="top"><p align="right">16,666</p></td>
<td width="10%" align="right" valign="top"><p align="right">17,970</p></td>
<td width="10%" align="right" valign="top"><p align="right">18,252</p></td>
<td width="10%" align="right" valign="top"><p align="right">17,695</p></td>
</tr>
<tr>
<td width="21%" align="left" valign="top"><p>Methadone Hydrochloride</p></td>
<td width="10%" align="right" valign="top"><p align="right">1,599</p></td>
<td width="10%" align="right" valign="top"><p align="right">6,523</p></td>
<td width="10%" align="right" valign="top"><p align="right">6,578</p></td>
<td width="10%" align="right" valign="top"><p align="right">6,182</p></td>
<td width="10%" align="right" valign="top"><p align="right">5,541</p></td>
<td width="10%" align="right" valign="top"><p align="right">3,696</p></td>
<td width="10%" align="right" valign="top"><p align="right">2,725</p></td>
<td width="10%" align="right" valign="top"><p align="right">2,231</p></td>
</tr>
<tr>
<td width="21%" align="left" valign="top"><p>Morphine</p></td>
<td width="10%" align="right" valign="top"><p align="right">16,170</p></td>
<td width="10%" align="right" valign="top"><p align="right">68,860</p></td>
<td width="10%" align="right" valign="top"><p align="right">78,627</p></td>
<td width="10%" align="right" valign="top"><p align="right">85,589</p></td>
<td width="10%" align="right" valign="top"><p align="right">88,853</p></td>
<td width="10%" align="right" valign="top"><p align="right">96,408</p></td>
<td width="10%" align="right" valign="top"><p align="right">104,556</p></td>
<td width="10%" align="right" valign="top"><p align="right">107,455</p></td>
</tr>
<tr>
<td width="21%" align="left" valign="top"><p>Morphine and cocaine with</p>
<p>chlorrpromazine</p></td>
<td width="10%" align="right" valign="top"><p align="right">0</p></td>
<td width="10%" align="right" valign="top"><p align="right">1</p></td>
<td width="10%" align="right" valign="top"><p align="right">1</p></td>
<td width="10%" align="right" valign="top"><p align="right">1</p></td>
<td width="10%" align="right" valign="top"><p align="right">0</p></td>
<td width="10%" align="right" valign="top"><p align="right">0</p></td>
<td width="10%" align="right" valign="top"><p align="right">0</p></td>
<td width="10%" align="right" valign="top"><p align="right">0</p></td>
</tr>
<tr>
<td width="21%" align="left" valign="top"><p>Morphine with cocaine</p></td>
<td width="10%" align="right" valign="top"><p align="right">0</p></td>
<td width="10%" align="right" valign="top"><p align="right">1</p></td>
<td width="10%" align="right" valign="top"><p align="right">2</p></td>
<td width="10%" align="right" valign="top"><p align="right">1</p></td>
<td width="10%" align="right" valign="top"><p align="right">0</p></td>
<td width="10%" align="right" valign="top"><p align="right">0</p></td>
<td width="10%" align="right" valign="top"><p align="right">0</p></td>
<td width="10%" align="right" valign="top"><p align="right">0</p></td>
</tr>
<tr>
<td width="21%" align="left" valign="top"><p>Morphine with cyclizine</p></td>
<td width="10%" align="right" valign="top"><p align="right">1,175</p></td>
<td width="10%" align="right" valign="top"><p align="right">4,695</p></td>
<td width="10%" align="right" valign="top"><p align="right">4,914</p></td>
<td width="10%" align="right" valign="top"><p align="right">4,534</p></td>
<td width="10%" align="right" valign="top"><p align="right">3,899</p></td>
<td width="10%" align="right" valign="top"><p align="right">3,870</p></td>
<td width="10%" align="right" valign="top"><p align="right">4,106</p></td>
<td width="10%" align="right" valign="top"><p align="right">3,760</p></td>
</tr>
<tr>
<td width="21%" align="left" valign="top"><p>Nalbuphine Hydrochloride</p></td>
<td width="10%" align="right" valign="top"><p align="right">0</p></td>
<td width="10%" align="right" valign="top"><p align="right">66</p></td>
<td width="10%" align="right" valign="top"><p align="right">77</p></td>
<td width="10%" align="right" valign="top"><p align="right">84</p></td>
<td width="10%" align="right" valign="top"><p align="right">101</p></td>
<td width="10%" align="right" valign="top"><p align="right">140</p></td>
<td width="10%" align="right" valign="top"><p align="right">181</p></td>
<td width="10%" align="right" valign="top"><p align="right">167</p></td>
</tr>
<tr>
<td width="21%" align="left" valign="top"><p>Opium</p></td>
<td width="10%" align="right" valign="top"><p align="right">8</p></td>
<td width="10%" align="right" valign="top"><p align="right">50</p></td>
<td width="10%" align="right" valign="top"><p align="right">46</p></td>
<td width="10%" align="right" valign="top"><p align="right">14</p></td>
<td width="10%" align="right" valign="top"><p align="right">0</p></td>
<td width="10%" align="right" valign="top"><p align="right">0</p></td>
<td width="10%" align="right" valign="top"><p align="right">0</p></td>
<td width="10%" align="right" valign="top"><p align="right">0</p></td>
</tr>
<tr>
<td width="21%" align="left" valign="top"><p>Oxycodone</p></td>
<td width="10%" align="right" valign="top"><p align="right">0</p></td>
<td width="10%" align="right" valign="top"><p align="right">0</p></td>
<td width="10%" align="right" valign="top"><p align="right">0</p></td>
<td width="10%" align="right" valign="top"><p align="right">0</p></td>
<td width="10%" align="right" valign="top"><p align="right">0</p></td>
<td width="10%" align="right" valign="top"><p align="right">0</p></td>
<td width="10%" align="right" valign="top"><p align="right">0</p></td>
<td width="10%" align="right" valign="top"><p align="right">119</p></td>
</tr>
<tr>
<td width="21%" align="left" valign="top"><p>Paracetamol with Tramadol Hydrochloride</p></td>
<td width="10%" align="right" valign="top"><p align="right">0</p></td>
<td width="10%" align="right" valign="top"><p align="right">0</p></td>
<td width="10%" align="right" valign="top"><p align="right">0</p></td>
<td width="10%" align="right" valign="top"><p align="right">0</p></td>
<td width="10%" align="right" valign="top"><p align="right">0</p></td>
<td width="10%" align="right" valign="top"><p align="right">0</p></td>
<td width="10%" align="right" valign="top"><p align="right">0</p></td>
<td width="10%" align="right" valign="top"><p align="right">0</p></td>
</tr>
<tr>
<td width="21%" align="left" valign="top"><p>Papaverine Hydrochloride</p></td>
<td width="10%" align="right" valign="top"><p align="right">32</p></td>
<td width="10%" align="right" valign="top"><p align="right">97</p></td>
<td width="10%" align="right" valign="top"><p align="right">68</p></td>
<td width="10%" align="right" valign="top"><p align="right">0</p></td>
<td width="10%" align="right" valign="top"><p align="right">0</p></td>
<td width="10%" align="right" valign="top"><p align="right">0</p></td>
<td width="10%" align="right" valign="top"><p align="right">0</p></td>
<td width="10%" align="right" valign="top"><p align="right">0</p></td>
</tr>
<tr>
<td width="21%" align="left" valign="top"><p>Pentazocine</p></td>
<td width="10%" align="right" valign="top"><p align="right">1,983</p></td>
<td width="10%" align="right" valign="top"><p align="right">7,638</p></td>
<td width="10%" align="right" valign="top"><p align="right">6,678</p></td>
<td width="10%" align="right" valign="top"><p align="right">5,625</p></td>
<td width="10%" align="right" valign="top"><p align="right">5,049</p></td>
<td width="10%" align="right" valign="top"><p align="right">4,259</p></td>
<td width="10%" align="right" valign="top"><p align="right">3,857</p></td>
<td width="10%" align="right" valign="top"><p align="right">3,420</p></td>
</tr>
<tr>
<td width="21%" align="left" valign="top"><p>Pethidine Hydrochloride</p></td>
<td width="10%" align="right" valign="top"><p align="right">3,869</p></td>
<td width="10%" align="right" valign="top"><p align="right">16,100</p></td>
<td width="10%" align="right" valign="top"><p align="right">17,086</p></td>
<td width="10%" align="right" valign="top"><p align="right">17,287</p></td>
<td width="10%" align="right" valign="top"><p align="right">16,410</p></td>
<td width="10%" align="right" valign="top"><p align="right">16,533</p></td>
<td width="10%" align="right" valign="top"><p align="right">16,682</p></td>
<td width="10%" align="right" valign="top"><p align="right">15,673</p></td>
</tr>
<tr>
<td width="21%" align="left" valign="top"><p>Pethidine with Promethazine</p></td>
<td width="10%" align="right" valign="top"><p align="right">4</p></td>
<td width="10%" align="right" valign="top"><p align="right">12</p></td>
<td width="10%" align="right" valign="top"><p align="right">8</p></td>
<td width="10%" align="right" valign="top"><p align="right">4</p></td>
<td width="10%" align="right" valign="top"><p align="right">3</p></td>
<td width="10%" align="right" valign="top"><p align="right">2</p></td>
<td width="10%" align="right" valign="top"><p align="right">1</p></td>
<td width="10%" align="right" valign="top"><p align="right">3</p></td>
</tr>
<tr>
<td width="21%" align="left" valign="top"><p>Phenazocine Hydrobromide</p></td>
<td width="10%" align="right" valign="top"><p align="right">112</p></td>
<td width="10%" align="right" valign="top"><p align="right">514</p></td>
<td width="10%" align="right" valign="top"><p align="right">554</p></td>
<td width="10%" align="right" valign="top"><p align="right">523</p></td>
<td width="10%" align="right" valign="top"><p align="right">551</p></td>
<td width="10%" align="right" valign="top"><p align="right">677</p></td>
<td width="10%" align="right" valign="top"><p align="right">608</p></td>
<td width="10%" align="right" valign="top"><p align="right">501</p></td>
</tr>
<tr>
<td width="21%" align="left" valign="top"><p>Phenoperidine Hydrochloride</p></td>
<td width="10%" align="right" valign="top"><p align="right">0</p></td>
<td width="10%" align="right" valign="top"><p align="right">1</p></td>
<td width="10%" align="right" valign="top"><p align="right">1</p></td>
<td width="10%" align="right" valign="top"><p align="right">0</p></td>
<td width="10%" align="right" valign="top"><p align="right">0</p></td>
<td width="10%" align="right" valign="top"><p align="right">1</p></td>
<td width="10%" align="right" valign="top"><p align="right">0</p></td>
<td width="10%" align="right" valign="top"><p align="right">0</p></td>
</tr>
<tr>
<td width="21%" align="left" valign="top"><p>Tramadol Hydrochloride</p></td>
<td width="10%" align="right" valign="top"><p align="right">0</p></td>
<td width="10%" align="right" valign="top"><p align="right">0</p></td>
<td width="10%" align="right" valign="top"><p align="right">23,469</p></td>
<td width="10%" align="right" valign="top"><p align="right">61,682</p></td>
<td width="10%" align="right" valign="top"><p align="right">101,504</p></td>
<td width="10%" align="right" valign="top"><p align="right">142,330</p></td>
<td width="10%" align="right" valign="top"><p align="right">178,639</p></td>
<td width="10%" align="right" valign="top"><p align="right">217,055</p></td>
</tr>
<tr>
<td width="21%" align="left" valign="top"><p>Total</p></td>
<td width="10%" align="right" valign="top"><p align="right">134,386</p></td>
<td width="10%" align="right" valign="top"><p align="right">569,517</p></td>
<td width="10%" align="right" valign="top"><p align="right">610,455</p></td>
<td width="10%" align="right" valign="top"><p align="right">645,979</p></td>
<td width="10%" align="right" valign="top"><p align="right">708,411</p></td>
<td width="10%" align="right" valign="top"><p align="right">780,704</p></td>
<td width="10%" align="right" valign="top"><p align="right">850,341</p></td>
<td width="10%" align="right" valign="top"> 904,390</td>
</tr>
</table></p>

  <p>Number of Prescribed Items (Continued)</p>

  <p><table width="75%" border="BORDER" cellpadding="2" cellspacing="0" bordercolor="#CCCCCC">
<tr>
<td width="21%" align="left" valign="top"> Year Ended 31 March</td>
<td width="10%" align="center" valign="top"> 2001</td>
<td width="11%" align="center" valign="top"> 2002</td>
<td width="11%" align="center" valign="top"> 2003</td>
<td width="11%" align="center" valign="top"> 2004</td>
<td width="11%" align="center" valign="top"> 2005</td>
<td width="11%" align="center" valign="top"> 2006</td>
<td width="11%" align="center" valign="top"> 2007</td>
</tr>
<tr>
<td width="21%" align="left" valign="top"> Buprenorphine</td>
<td width="10%" align="right" valign="top"> 6,107</td>
<td width="11%" align="right" valign="top"> 5,473</td>
<td width="11%" align="right" valign="top"> 7,011</td>
<td width="11%" align="right" valign="top"> 9,671</td>
<td width="11%" align="right" valign="top"> 12,020</td>
<td width="11%" align="right" valign="top"> 15,669</td>
<td width="11%" align="right" valign="top"> 28,757</td>
</tr>
<tr>
<td width="21%" align="left" valign="top"> Codeine Phosphate</td>
<td width="10%" align="right" valign="top"> 57,870</td>
<td width="11%" align="right" valign="top"> 57,637</td>
<td width="11%" align="right" valign="top"> 59,030</td>
<td width="11%" align="right" valign="top"> 60,275</td>
<td width="11%" align="right" valign="top"> 61,929</td>
<td width="11%" align="right" valign="top"> 66,427</td>
<td width="11%" align="right" valign="top"> 68,876</td>
</tr>
<tr>
<td width="21%" align="left" valign="top"> Dextromoramide</td>
<td width="10%" align="right" valign="top"> 3,505</td>
<td width="11%" align="right" valign="top"> 3,386</td>
<td width="11%" align="right" valign="top"> 3,303</td>
<td width="11%" align="right" valign="top"> 606</td>
<td width="11%" align="right" valign="top"> 0</td>
<td width="11%" align="right" valign="top"> 0</td>
<td width="11%" align="right" valign="top"> 0</td>
</tr>
<tr>
<td width="21%" align="left" valign="top"> Dextropropoxyphene Hydrocholride</td>
<td width="10%" align="right" valign="top"> 1,216</td>
<td width="11%" align="right" valign="top"> 965</td>
<td width="11%" align="right" valign="top"> 736</td>
<td width="11%" align="right" valign="top"> 477</td>
<td width="11%" align="right" valign="top"> 37</td>
<td width="11%" align="right" valign="top"> 0</td>
<td width="11%" align="right" valign="top"> 0</td>
</tr>
<tr>
<td width="21%" align="left" valign="top"> Diamorphine Hydrochloride</td>
<td width="10%" align="right" valign="top"> 11,839</td>
<td width="11%" align="right" valign="top"> 12,707</td>
<td width="11%" align="right" valign="top"> 13,034</td>
<td width="11%" align="right" valign="top"> 12,388</td>
<td width="11%" align="right" valign="top"> 11,731</td>
<td width="11%" align="right" valign="top"> 6,568</td>
<td width="11%" align="right" valign="top"> 7,107</td>
</tr>
<tr>
<td width="21%" align="left" valign="top"> Dihydrocodeine Tartrate</td>
<td width="10%" align="right" valign="top"> 438,558</td>
<td width="11%" align="right" valign="top"> 440,167</td>
<td width="11%" align="right" valign="top"> 437,288</td>
<td width="11%" align="right" valign="top"> 436,045</td>
<td width="11%" align="right" valign="top"> 430,985</td>
<td width="11%" align="right" valign="top"> 432,504</td>
<td width="11%" align="right" valign="top"> 433,891</td>
</tr>
<tr>
<td width="21%" align="left" valign="top"> Dipipanone with Cyclizine</td>
<td width="10%" align="right" valign="top"> 6,983</td>
<td width="11%" align="right" valign="top"> 6,608</td>
<td width="11%" align="right" valign="top"> 6,098</td>
<td width="11%" align="right" valign="top"> 5,913</td>
<td width="11%" align="right" valign="top"> 5,412</td>
<td width="11%" align="right" valign="top"> 5,015</td>
<td width="11%" align="right" valign="top"> 4,885</td>
</tr>
<tr>
<td width="21%" align="left" valign="top"> Fentanyl</td>
<td width="10%" align="right" valign="top"> 13,154</td>
<td width="11%" align="right" valign="top"> 17,237</td>
<td width="11%" align="right" valign="top"> 22,461</td>
<td width="11%" align="right" valign="top"> 26,850</td>
<td width="11%" align="right" valign="top"> 30,780</td>
<td width="11%" align="right" valign="top"> 38,094</td>
<td width="11%" align="right" valign="top"> 46,421</td>
</tr>
<tr>
<td width="21%" align="left" valign="top"> Hydromorphone Hydrochloride</td>
<td width="10%" align="right" valign="top"> 4,407</td>
<td width="11%" align="right" valign="top"> 3,022</td>
<td width="11%" align="right" valign="top"> 2,230</td>
<td width="11%" align="right" valign="top"> 2,026</td>
<td width="11%" align="right" valign="top"> 2,122</td>
<td width="11%" align="right" valign="top"> 2,378</td>
<td width="11%" align="right" valign="top"> 2,720</td>
</tr>
<tr>
<td width="21%" align="left" valign="top"> Meptazinol</td>
<td width="10%" align="right" valign="top"> 16,362</td>
<td width="11%" align="right" valign="top"> 14,583</td>
<td width="11%" align="right" valign="top"> 13,196</td>
<td width="11%" align="right" valign="top"> 12,113</td>
<td width="11%" align="right" valign="top"> 11,629</td>
<td width="11%" align="right" valign="top"> 11,329</td>
<td width="11%" align="right" valign="top"> 10,819</td>
</tr>
<tr>
<td width="21%" align="left" valign="top"> Methadone Hydrochloride</td>
<td width="10%" align="right" valign="top"> 1,848</td>
<td width="11%" align="right" valign="top"> 1,498</td>
<td width="11%" align="right" valign="top"> 1,609</td>
<td width="11%" align="right" valign="top"> 1,820</td>
<td width="11%" align="right" valign="top"> 1,971</td>
<td width="11%" align="right" valign="top"> 1,771</td>
<td width="11%" align="right" valign="top"> 2,119</td>
</tr>
<tr>
<td width="21%" align="left" valign="top"> Morphine</td>
<td width="10%" align="right" valign="top"> 113,258</td>
<td width="11%" align="right" valign="top"> 119,753</td>
<td width="11%" align="right" valign="top"> 127,146</td>
<td width="11%" align="right" valign="top"> 132,440</td>
<td width="11%" align="right" valign="top"> 143,330</td>
<td width="11%" align="right" valign="top"> 162,157</td>
<td width="11%" align="right" valign="top"> 181,821</td>
</tr>
<tr>
<td width="21%" align="left" valign="top"> Morphine and cocaine with Chlorpromazine</td>
<td width="10%" align="right" valign="top"> 0</td>
<td width="11%" align="right" valign="top"> 0</td>
<td width="11%" align="right" valign="top"> 0</td>
<td width="11%" align="right" valign="top"> 0</td>
<td width="11%" align="right" valign="top"> 0</td>
<td width="11%" align="right" valign="top"> 0</td>
<td width="11%" align="right" valign="top"> 0</td>
</tr>
<tr>
<td width="21%" align="left" valign="top"> Morphine with cocaine</td>
<td width="10%" align="right" valign="top"> 0</td>
<td width="11%" align="right" valign="top"> 0</td>
<td width="11%" align="right" valign="top"> 0</td>
<td width="11%" align="right" valign="top"> 0</td>
<td width="11%" align="right" valign="top"> 0</td>
<td width="11%" align="right" valign="top"> 0</td>
<td width="11%" align="right" valign="top"> 0</td>
</tr>
<tr>
<td width="21%" align="left" valign="top"> Morphine with cyclizine</td>
<td width="10%" align="right" valign="top"> 3,636</td>
<td width="11%" align="right" valign="top"> 3,367</td>
<td width="11%" align="right" valign="top"> 3,041</td>
<td width="11%" align="right" valign="top"> 3,007</td>
<td width="11%" align="right" valign="top"> 2,697</td>
<td width="11%" align="right" valign="top"> 2,591</td>
<td width="11%" align="right" valign="top"> 2,150</td>
</tr>
<tr>
<td width="21%" align="left" valign="top"> Nalbuphine Hydrochloride</td>
<td width="10%" align="right" valign="top"> 286</td>
<td width="11%" align="right" valign="top"> 267</td>
<td width="11%" align="right" valign="top"> 275</td>
<td width="11%" align="right" valign="top"> 259</td>
<td width="11%" align="right" valign="top"> 98</td>
<td width="11%" align="right" valign="top"> 0</td>
<td width="11%" align="right" valign="top"> 0</td>
</tr>
<tr>
<td width="21%" align="left" valign="top"> Opium</td>
<td width="10%" align="right" valign="top"> 0</td>
<td width="11%" align="right" valign="top"> 0</td>
<td width="11%" align="right" valign="top"> 0</td>
<td width="11%" align="right" valign="top"> 0</td>
<td width="11%" align="right" valign="top"> 0</td>
<td width="11%" align="right" valign="top"> 0</td>
<td width="11%" align="right" valign="top"> 0</td>
</tr>
<tr>
<td width="21%" align="left" valign="top"> Oxycodone</td>
<td width="10%" align="right" valign="top"> 5,562</td>
<td width="11%" align="right" valign="top"> 13,922</td>
<td width="11%" align="right" valign="top"> 23,206</td>
<td width="11%" align="right" valign="top"> 33,591</td>
<td width="11%" align="right" valign="top"> 45,237</td>
<td width="11%" align="right" valign="top"> 58,452</td>
<td width="11%" align="right" valign="top"> 74,519</td>
</tr>
<tr>
<td width="21%" align="left" valign="top"> Paracetamol with Tramadol Hydrochloride</td>
<td width="10%" align="right" valign="top"> 0</td>
<td width="11%" align="right" valign="top"> 0</td>
<td width="11%" align="right" valign="top"> 0</td>
<td width="11%" align="right" valign="top"> 0</td>
<td width="11%" align="right" valign="top"> 4,512</td>
<td width="11%" align="right" valign="top"> 16,498</td>
<td width="11%" align="right" valign="top"> 21,341</td>
</tr>
<tr>
<td width="21%" align="left" valign="top"> Papaverine Hydrochloride</td>
<td width="10%" align="right" valign="top"> 0</td>
<td width="11%" align="right" valign="top"> 0</td>
<td width="11%" align="right" valign="top"> 0</td>
<td width="11%" align="right" valign="top"> 0</td>
<td width="11%" align="right" valign="top"> 0</td>
<td width="11%" align="right" valign="top"> 0</td>
<td width="11%" align="right" valign="top"> 0</td>
</tr>
<tr>
<td width="21%" align="left" valign="top"> Pentazocine</td>
<td width="10%" align="right" valign="top"> 2,720</td>
<td width="11%" align="right" valign="top"> 2,314</td>
<td width="11%" align="right" valign="top"> 2,163</td>
<td width="11%" align="right" valign="top"> 2,001</td>
<td width="11%" align="right" valign="top"> 1,671</td>
<td width="11%" align="right" valign="top"> 1,446</td>
<td width="11%" align="right" valign="top"> 1,231</td>
</tr>
<tr>
<td width="21%" align="left" valign="top"> Pethidine Hydrochloride</td>
<td width="10%" align="right" valign="top"> 15,673</td>
<td width="11%" align="right" valign="top"> 15,076</td>
<td width="11%" align="right" valign="top"> 14,171</td>
<td width="11%" align="right" valign="top"> 13,250</td>
<td width="11%" align="right" valign="top"> 12,257</td>
<td width="11%" align="right" valign="top"> 10,825</td>
<td width="11%" align="right" valign="top"> 10,773</td>
</tr>
<tr>
<td width="21%" align="left" valign="top"> Pethidine with Promethazine</td>
<td width="10%" align="right" valign="top"> 3</td>
<td width="11%" align="right" valign="top"> 2</td>
<td width="11%" align="right" valign="top"> 1</td>
<td width="11%" align="right" valign="top"> 1</td>
<td width="11%" align="right" valign="top"> 1</td>
<td width="11%" align="right" valign="top"> 0</td>
<td width="11%" align="right" valign="top"> 0</td>
</tr>
<tr>
<td width="21%" align="left" valign="top"> Phenazocine Hydrobromide</td>
<td width="10%" align="right" valign="top"> 0</td>
<td width="11%" align="right" valign="top"> 0</td>
<td width="11%" align="right" valign="top"> 0</td>
<td width="11%" align="right" valign="top"> 0</td>
<td width="11%" align="right" valign="top"> 0</td>
<td width="11%" align="right" valign="top"> 0</td>
<td width="11%" align="right" valign="top"> 0</td>
</tr>
<tr>
<td width="21%" align="left" valign="top"> Phenoperidne Hydrochloride</td>
<td width="10%" align="right" valign="top"> 0</td>
<td width="11%" align="right" valign="top"> 0</td>
<td width="11%" align="right" valign="top"> 0</td>
<td width="11%" align="right" valign="top"> 0</td>
<td width="11%" align="right" valign="top"> 0</td>
<td width="11%" align="right" valign="top"> 0</td>
<td width="11%" align="right" valign="top"> 0</td>
</tr>
<tr>
<td width="21%" align="left" valign="top"> Tramadol Hydrochloride</td>
<td width="10%" align="right" valign="top"> 271,859</td>
<td width="11%" align="right" valign="top"> 333,541</td>
<td width="11%" align="right" valign="top"> 402,801</td>
<td width="11%" align="right" valign="top"> 471,035</td>
<td width="11%" align="right" valign="top"> 533,319</td>
<td width="11%" align="right" valign="top"> 625,109</td>
<td width="11%" align="right" valign="top"> 706,223</td>
</tr>
<tr>
<td width="21%" align="left" valign="top"> Total</td>
<td width="10%" align="right" valign="top"> 974,846</td>
<td width="11%" align="right" valign="top"> 1,051,525</td>
<td width="11%" align="right" valign="top"> 1,138,800</td>
<td width="11%" align="right" valign="top"> 1,223,768</td>
<td width="11%" align="right" valign="top"> 1,311,738</td>
<td width="11%" align="right" valign="top"> 1,456,833</td>
<td width="11%" align="right" valign="top"> 1,603,653</td>
</tr>
</table></p>

  <p>Gross Ingredient Cost (&pound;)</p>

  <p><table width="75%" border="BORDER" cellpadding="2" cellspacing="0" bordercolor="#CCCCCC">
<tr>
<td width="20%" align="left" valign="top"> Year Ended 31 March</td>
<td width="10%" align="center" valign="top"> 1993</td>
<td width="10%" align="center" valign="top"> 1994</td>
<td width="10%" align="center" valign="top"> 1995</td>
<td width="10%" align="center" valign="top"> 1996</td>
<td width="10%" align="center" valign="top"> 1997</td>
<td width="11%" align="center" valign="top"> 1998</td>
<td width="11%" align="center" valign="top"> 1999</td>
<td width="11%" align="center" valign="top"> 2000</td>
</tr>
<tr>
<td width="20%" align="left" valign="top"> Buprenorphine</td>
<td width="10%" align="right" valign="top"> 71,578</td>
<td width="10%" align="right" valign="top"> 269,327</td>
<td width="10%" align="right" valign="top"> 198,382</td>
<td width="10%" align="right" valign="top"> 155,999</td>
<td width="10%" align="right" valign="top"> 132,224</td>
<td width="11%" align="right" valign="top"> 111,832</td>
<td width="11%" align="right" valign="top"> 95,702</td>
<td width="11%" align="right" valign="top"> 84,125</td>
</tr>
<tr>
<td width="20%" align="left" valign="top"> Codeine Phosphate</td>
<td width="10%" align="right" valign="top"> 21,329</td>
<td width="10%" align="right" valign="top"> 88,013</td>
<td width="10%" align="right" valign="top"> 94,159</td>
<td width="10%" align="right" valign="top"> 95,136</td>
<td width="10%" align="right" valign="top"> 100,875</td>
<td width="11%" align="right" valign="top"> 109,162</td>
<td width="11%" align="right" valign="top"> 126,957</td>
<td width="11%" align="right" valign="top"> 304,547</td>
</tr>
<tr>
<td width="20%" align="left" valign="top"> Dextromoramide</td>
<td width="10%" align="right" valign="top"> 9,536</td>
<td width="10%" align="right" valign="top"> 42,038</td>
<td width="10%" align="right" valign="top"> 38,950</td>
<td width="10%" align="right" valign="top"> 37,356</td>
<td width="10%" align="right" valign="top"> 33,572</td>
<td width="11%" align="right" valign="top"> 35,687</td>
<td width="11%" align="right" valign="top"> 32,760</td>
<td width="11%" align="right" valign="top"> 26,305</td>
</tr>
<tr>
<td width="20%" align="left" valign="top"> Dextropropoxyphene Hydrochloride</td>
<td width="10%" align="right" valign="top"> 1,329</td>
<td width="10%" align="right" valign="top"> 6,460</td>
<td width="10%" align="right" valign="top"> 5,387</td>
<td width="10%" align="right" valign="top"> 5,590</td>
<td width="10%" align="right" valign="top"> 5,622</td>
<td width="11%" align="right" valign="top"> 4,840</td>
<td width="11%" align="right" valign="top"> 4,796</td>
<td width="11%" align="right" valign="top"> 4,262</td>
</tr>
<tr>
<td width="20%" align="left" valign="top"> Diamorphine Hydrochloride</td>
<td width="10%" align="right" valign="top"> 106,261</td>
<td width="10%" align="right" valign="top"> 406,431</td>
<td width="10%" align="right" valign="top"> 477,584</td>
<td width="10%" align="right" valign="top"> 429,424</td>
<td width="10%" align="right" valign="top"> 428,610</td>
<td width="11%" align="right" valign="top"> 376,742</td>
<td width="11%" align="right" valign="top"> 333,333</td>
<td width="11%" align="right" valign="top"> 394,066</td>
</tr>
<tr>
<td width="20%" align="left" valign="top"> Dihydrocodeine Tartrate</td>
<td width="10%" align="right" valign="top"> 281,691</td>
<td width="10%" align="right" valign="top"> 1,280,646</td>
<td width="10%" align="right" valign="top"> 1,381,572</td>
<td width="10%" align="right" valign="top"> 1,253,929</td>
<td width="10%" align="right" valign="top"> 1,309,074</td>
<td width="11%" align="right" valign="top"> 1,478,041</td>
<td width="11%" align="right" valign="top"> 1,590,516</td>
<td width="11%" align="right" valign="top"> 2,375,759</td>
</tr>
<tr>
<td width="20%" align="left" valign="top"> Dipipanone with Cyclizine</td>
<td width="10%" align="right" valign="top"> 18,938</td>
<td width="10%" align="right" valign="top"> 78,286</td>
<td width="10%" align="right" valign="top"> 84,345</td>
<td width="10%" align="right" valign="top"> 82,050</td>
<td width="10%" align="right" valign="top"> 80,886</td>
<td width="11%" align="right" valign="top"> 73,360</td>
<td width="11%" align="right" valign="top"> 66,994</td>
<td width="11%" align="right" valign="top"> 64,121</td>
</tr>
<tr>
<td width="20%" align="left" valign="top"> Fentanyl</td>
<td width="10%" align="right" valign="top"> 0</td>
<td width="10%" align="right" valign="top"> 0</td>
<td width="10%" align="right" valign="top"> 18,950</td>
<td width="10%" align="right" valign="top"> 300,845</td>
<td width="10%" align="right" valign="top"> 598,326</td>
<td width="11%" align="right" valign="top"> 808,991</td>
<td width="11%" align="right" valign="top"> 1,022,698</td>
<td width="11%" align="right" valign="top"> 1,098,924</td>
</tr>
<tr>
<td width="20%" align="left" valign="top"> Hydromorphone Hydrochloride</td>
<td width="10%" align="right" valign="top"> 0</td>
<td width="10%" align="right" valign="top"> 0</td>
<td width="10%" align="right" valign="top"> 0</td>
<td width="10%" align="right" valign="top"> 0</td>
<td width="10%" align="right" valign="top"> 0</td>
<td width="11%" align="right" valign="top"> 34,354</td>
<td width="11%" align="right" valign="top"> 103,814</td>
<td width="11%" align="right" valign="top"> 154,301</td>
</tr>
<tr>
<td width="20%" align="left" valign="top"> Meptazinol</td>
<td width="10%" align="right" valign="top"> 52,950</td>
<td width="10%" align="right" valign="top"> 235,846</td>
<td width="10%" align="right" valign="top"> 256,290</td>
<td width="10%" align="right" valign="top"> 272,645</td>
<td width="10%" align="right" valign="top"> 293,212</td>
<td width="11%" align="right" valign="top"> 322,896</td>
<td width="11%" align="right" valign="top"> 334,506</td>
<td width="11%" align="right" valign="top"> 343,313</td>
</tr>
<tr>
<td width="20%" align="left" valign="top"> Methadone Hydrochloride</td>
<td width="10%" align="right" valign="top"> 24,463</td>
<td width="10%" align="right" valign="top"> 85,622</td>
<td width="10%" align="right" valign="top"> 71,626</td>
<td width="10%" align="right" valign="top"> 78,158</td>
<td width="10%" align="right" valign="top"> 71,185</td>
<td width="11%" align="right" valign="top"> 51,727</td>
<td width="11%" align="right" valign="top"> 33,119</td>
<td width="11%" align="right" valign="top"> 24,023</td>
</tr>
<tr>
<td width="20%" align="left" valign="top"> Morphine</td>
<td width="10%" align="right" valign="top"> 311,946</td>
<td width="10%" align="right" valign="top"> 1,372,177</td>
<td width="10%" align="right" valign="top"> 1,565,245</td>
<td width="10%" align="right" valign="top"> 1,716,888</td>
<td width="10%" align="right" valign="top"> 1,716,855</td>
<td width="11%" align="right" valign="top"> 1,850,828</td>
<td width="11%" align="right" valign="top"> 1,998,005</td>
<td width="11%" align="right" valign="top"> 1,987,443</td>
</tr>
<tr>
<td width="20%" align="left" valign="top"> Morphine and cocaine with Chlorpromazine</td>
<td width="10%" align="right" valign="top"> 0</td>
<td width="10%" align="right" valign="top"> 1</td>
<td width="10%" align="right" valign="top"> 3</td>
<td width="10%" align="right" valign="top"> 1</td>
<td width="10%" align="right" valign="top"> 0</td>
<td width="11%" align="right" valign="top"> 0</td>
<td width="11%" align="right" valign="top"> 0</td>
<td width="11%" align="right" valign="top"> 0</td>
</tr>
<tr>
<td width="20%" align="left" valign="top"> Morphine with cocaine</td>
<td width="10%" align="right" valign="top"> 0</td>
<td width="10%" align="right" valign="top"> 6</td>
<td width="10%" align="right" valign="top"> 6</td>
<td width="10%" align="right" valign="top"> 2</td>
<td width="10%" align="right" valign="top"> 0</td>
<td width="11%" align="right" valign="top"> 0</td>
<td width="11%" align="right" valign="top"> 0</td>
<td width="11%" align="right" valign="top"> 0</td>
</tr>
<tr>
<td width="20%" align="left" valign="top"> Morphine with cyclizine</td>
<td width="10%" align="right" valign="top"> 10,227</td>
<td width="10%" align="right" valign="top"> 41,431</td>
<td width="10%" align="right" valign="top"> 45,593</td>
<td width="10%" align="right" valign="top"> 47,051</td>
<td width="10%" align="right" valign="top"> 41,371</td>
<td width="11%" align="right" valign="top"> 47,957</td>
<td width="11%" align="right" valign="top"> 40,449</td>
<td width="11%" align="right" valign="top"> 38,695</td>
</tr>
<tr>
<td width="20%" align="left" valign="top"> Nalbuphine Hydrocholride</td>
<td width="10%" align="right" valign="top"> 0</td>
<td width="10%" align="right" valign="top"> 83,722</td>
<td width="10%" align="right" valign="top"> 16,790</td>
<td width="10%" align="right" valign="top"> 3,116</td>
<td width="10%" align="right" valign="top"> 3,612</td>
<td width="11%" align="right" valign="top"> 4,523</td>
<td width="11%" align="right" valign="top"> 5,256</td>
<td width="11%" align="right" valign="top"> 3,590</td>
</tr>
<tr>
<td width="20%" align="left" valign="top"> Opium</td>
<td width="10%" align="right" valign="top"> 8</td>
<td width="10%" align="right" valign="top"> 40</td>
<td width="10%" align="right" valign="top"> 36</td>
<td width="10%" align="right" valign="top"> 14</td>
<td width="10%" align="right" valign="top"> 0</td>
<td width="11%" align="right" valign="top"> 0</td>
<td width="11%" align="right" valign="top"> 0</td>
<td width="11%" align="right" valign="top"> 0</td>
</tr>
<tr>
<td width="20%" align="left" valign="top"> Oxycodone</td>
<td width="10%" align="right" valign="top"> 0</td>
<td width="10%" align="right" valign="top"> 0</td>
<td width="10%" align="right" valign="top"> 0</td>
<td width="10%" align="right" valign="top"> 0</td>
<td width="10%" align="right" valign="top"> 0</td>
<td width="11%" align="right" valign="top"> 0</td>
<td width="11%" align="right" valign="top"> 0</td>
<td width="11%" align="right" valign="top"> 4,385</td>
</tr>
<tr>
<td width="20%" align="left" valign="top"> Paracetamol with Tramadol Hydrochloride</td>
<td width="10%" align="right" valign="top"> 0</td>
<td width="10%" align="right" valign="top"> 0</td>
<td width="10%" align="right" valign="top"> 0</td>
<td width="10%" align="right" valign="top"> 0</td>
<td width="10%" align="right" valign="top"> 0</td>
<td width="11%" align="right" valign="top"> 0</td>
<td width="11%" align="right" valign="top"> 0</td>
<td width="11%" align="right" valign="top"> 0</td>
</tr>
<tr>
<td width="20%" align="left" valign="top"> Papaverine Hydrochloride</td>
<td width="10%" align="right" valign="top"> 336</td>
<td width="10%" align="right" valign="top"> 1,403</td>
<td width="10%" align="right" valign="top"> 807</td>
<td width="10%" align="right" valign="top"> 0</td>
<td width="10%" align="right" valign="top"> 0</td>
<td width="11%" align="right" valign="top"> 0</td>
<td width="11%" align="right" valign="top"> 0</td>
<td width="11%" align="right" valign="top"> 0</td>
</tr>
<tr>
<td width="20%" align="left" valign="top"> Pentazocine</td>
<td width="10%" align="right" valign="top"> 20,697</td>
<td width="10%" align="right" valign="top"> 88,391</td>
<td width="10%" align="right" valign="top"> 84,588</td>
<td width="10%" align="right" valign="top"> 68,690</td>
<td width="10%" align="right" valign="top"> 62,029</td>
<td width="11%" align="right" valign="top"> 56,447</td>
<td width="11%" align="right" valign="top"> 55,670</td>
<td width="11%" align="right" valign="top"> 51,254</td>
</tr>
<tr>
<td width="20%" align="left" valign="top"> Pethidine Hydrochloride</td>
<td width="10%" align="right" valign="top"> 3,235</td>
<td width="10%" align="right" valign="top"> 13,744</td>
<td width="10%" align="right" valign="top"> 15,783</td>
<td width="10%" align="right" valign="top"> 46,063</td>
<td width="10%" align="right" valign="top"> 60,999</td>
<td width="11%" align="right" valign="top"> 71,137</td>
<td width="11%" align="right" valign="top"> 73,253</td>
<td width="11%" align="right" valign="top"> 87,516</td>
</tr>
<tr>
<td width="20%" align="left" valign="top"> Pethidine with Promethazine</td>
<td width="10%" align="right" valign="top"> 22</td>
<td width="10%" align="right" valign="top"> 51</td>
<td width="10%" align="right" valign="top"> 49</td>
<td width="10%" align="right" valign="top"> 22</td>
<td width="10%" align="right" valign="top"> 17</td>
<td width="11%" align="right" valign="top"> 17</td>
<td width="11%" align="right" valign="top"> 7</td>
<td width="11%" align="right" valign="top"> 11</td>
</tr>
<tr>
<td width="20%" align="left" valign="top"> Phenazocine Hydrobromide</td>
<td width="10%" align="right" valign="top"> 2,545</td>
<td width="10%" align="right" valign="top"> 13,192</td>
<td width="10%" align="right" valign="top"> 14,800</td>
<td width="10%" align="right" valign="top"> 15,834</td>
<td width="10%" align="right" valign="top"> 16,593</td>
<td width="11%" align="right" valign="top"> 20,252</td>
<td width="11%" align="right" valign="top"> 18,672</td>
<td width="11%" align="right" valign="top"> 12,588</td>
</tr>
<tr>
<td width="20%" align="left" valign="top"> Phenoperidine Hydrochloride</td>
<td width="10%" align="right" valign="top"> 0</td>
<td width="10%" align="right" valign="top"> 2</td>
<td width="10%" align="right" valign="top"> 2</td>
<td width="10%" align="right" valign="top"> 0</td>
<td width="10%" align="right" valign="top"> 0</td>
<td width="11%" align="right" valign="top"> 5</td>
<td width="11%" align="right" valign="top"> 0</td>
<td width="11%" align="right" valign="top"> 0</td>
</tr>
<tr>
<td width="20%" align="left" valign="top"> Tramadol Hydrochloride</td>
<td width="10%" align="right" valign="top"> 937,093</td>
<td width="10%" align="right" valign="top"> 4,106,829</td>
<td width="10%" align="right" valign="top"> 4,370,947</td>
<td width="10%" align="right" valign="top"> 4,608,811</td>
<td width="10%" align="right" valign="top"> 4,955,063</td>
<td width="11%" align="right" valign="top"> 5,458,799</td>
<td width="11%" align="right" valign="top"> 5,936,507</td>
<td width="11%" align="right" valign="top"> 7,062,976</td>
</tr>
<tr>
<td width="20%" align="left" valign="top"> Total</td>
<td width="10%" align="right" valign="top"> 1,874,187</td>
<td width="10%" align="right" valign="top"> 8,213,658</td>
<td width="10%" align="right" valign="top"> 8,741,893</td>
<td width="10%" align="right" valign="top"> 9,217,622</td>
<td width="10%" align="right" valign="top"> 9,910,125</td>
<td width="11%" align="right" valign="top"> 10,917,598</td>
<td width="11%" align="right" valign="top"> 11,873,015</td>
<td width="11%" align="right" valign="top"> 14,125,953</td>
</tr>
</table></p>

  <p>Gross Ingredient Cost (&pound;) (Continued)</p>

  <p><table width="75%" border="BORDER" cellpadding="2" cellspacing="0" bordercolor="#CCCCCC">
<tr>
<td width="20%" valign="top"> Year ended 31 March</td>
<td width="11%" align="center" valign="top"> 2001</td>
<td width="11%" align="center" valign="top"> 2002</td>
<td width="11%" align="center" valign="top"> 2003</td>
<td width="11%" align="center" valign="top"> 2004</td>
<td width="11%" align="center" valign="top"> 2005</td>
<td width="11%" align="center" valign="top"> 2006</td>
<td width="11%" align="center" valign="top"> 2007</td>
</tr>
<tr>
<td width="20%" align="left" valign="top"> Buprenorphine</td>
<td width="11%" align="right" valign="top"> 70,486</td>
<td width="11%" align="right" valign="top"> 64,729</td>
<td width="11%" align="right" valign="top"> 172,639</td>
<td width="11%" align="right" valign="top"> 355,844</td>
<td width="11%" align="right" valign="top"> 522,518</td>
<td width="11%" align="right" valign="top"> 707,918</td>
<td width="11%" align="right" valign="top"> 1,344,903</td>
</tr>
<tr>
<td width="20%" align="left" valign="top"> Codeine Phosphate</td>
<td width="11%" align="right" valign="top"> 322,690</td>
<td width="11%" align="right" valign="top"> 280,466</td>
<td width="11%" align="right" valign="top"> 287,418</td>
<td width="11%" align="right" valign="top"> 294,912</td>
<td width="11%" align="right" valign="top"> 298,692</td>
<td width="11%" align="right" valign="top"> 371,879</td>
<td width="11%" align="right" valign="top"> 492,260</td>
</tr>
<tr>
<td width="20%" align="left" valign="top"> Dextromoramide</td>
<td width="11%" align="right" valign="top"> 22,503</td>
<td width="11%" align="right" valign="top"> 23,851</td>
<td width="11%" align="right" valign="top"> 24,198</td>
<td width="11%" align="right" valign="top"> 3,846</td>
<td width="11%" align="right" valign="top"> 0</td>
<td width="11%" align="right" valign="top"> 0</td>
<td width="11%" align="right" valign="top"> 0</td>
</tr>
<tr>
<td width="20%" align="left" valign="top"> Dextropropoxyphene Hydrochlodide</td>
<td width="11%" align="right" valign="top"> 11,661</td>
<td width="11%" align="right" valign="top"> 9,555</td>
<td width="11%" align="right" valign="top"> 6,839</td>
<td width="11%" align="right" valign="top"> 4,209</td>
<td width="11%" align="right" valign="top"> 334</td>
<td width="11%" align="right" valign="top"> 0</td>
<td width="11%" align="right" valign="top"> 0</td>
</tr>
<tr>
<td width="20%" align="left" valign="top"> Diamorphine Hydrochloride</td>
<td width="11%" align="right" valign="top"> 371,684</td>
<td width="11%" align="right" valign="top"> 414,378</td>
<td width="11%" align="right" valign="top"> 360,239</td>
<td width="11%" align="right" valign="top"> 291,943</td>
<td width="11%" align="right" valign="top"> 238,779</td>
<td width="11%" align="right" valign="top"> 136,279</td>
<td width="11%" align="right" valign="top"> 234,933</td>
</tr>
<tr>
<td width="20%" align="left" valign="top"> Dihydrocodeine Tartrate</td>
<td width="11%" align="right" valign="top"> 2,362,362</td>
<td width="11%" align="right" valign="top"> 2,203,650</td>
<td width="11%" align="right" valign="top"> 2,304,317</td>
<td width="11%" align="right" valign="top"> 2,345,958</td>
<td width="11%" align="right" valign="top"> 2,355,434</td>
<td width="11%" align="right" valign="top"> 2,441,864</td>
<td width="11%" align="right" valign="top"> 2,776,922</td>
</tr>
<tr>
<td width="20%" align="left" valign="top"> Dipipanone with Cyclizine</td>
<td width="11%" align="right" valign="top"> 59,793</td>
<td width="11%" align="right" valign="top"> 57,804</td>
<td width="11%" align="right" valign="top"> 55,417</td>
<td width="11%" align="right" valign="top"> 55,209</td>
<td width="11%" align="right" valign="top"> 52,669</td>
<td width="11%" align="right" valign="top"> 59,795</td>
<td width="11%" align="right" valign="top"> 62,713</td>
</tr>
<tr>
<td width="20%" align="left" valign="top"> Fentanyl</td>
<td width="11%" align="right" valign="top"> 1,239.088</td>
<td width="11%" align="right" valign="top"> 1,731,628</td>
<td width="11%" align="right" valign="top"> 2,205,524</td>
<td width="11%" align="right" valign="top"> 2,640,152</td>
<td width="11%" align="right" valign="top"> 3,056,123</td>
<td width="11%" align="right" valign="top"> 3,606,716</td>
<td width="11%" align="right" valign="top"> 4,201,648</td>
</tr>
<tr>
<td width="20%" align="left" valign="top"> Hydromorphone Hydrochloride</td>
<td width="11%" align="right" valign="top"> 169,125</td>
<td width="11%" align="right" valign="top"> 130,419</td>
<td width="11%" align="right" valign="top"> 90,003</td>
<td width="11%" align="right" valign="top"> 99,262</td>
<td width="11%" align="right" valign="top"> 105,295</td>
<td width="11%" align="right" valign="top"> 118,336</td>
<td width="11%" align="right" valign="top"> 132,387</td>
</tr>
<tr>
<td width="20%" align="left" valign="top"> Meptazinol</td>
<td width="11%" align="right" valign="top"> 328,338</td>
<td width="11%" align="right" valign="top"> 280,750</td>
<td width="11%" align="right" valign="top"> 249,237</td>
<td width="11%" align="right" valign="top"> 233,037</td>
<td width="11%" align="right" valign="top"> 230,595</td>
<td width="11%" align="right" valign="top"> 228,063</td>
<td width="11%" align="right" valign="top"> 223,602</td>
</tr>
<tr>
<td width="20%" align="left" valign="top"> Methadone Hydrochloride</td>
<td width="11%" align="right" valign="top"> 23,526</td>
<td width="11%" align="right" valign="top"> 18,206</td>
<td width="11%" align="right" valign="top"> 21,760</td>
<td width="11%" align="right" valign="top"> 21,634</td>
<td width="11%" align="right" valign="top"> 24,125</td>
<td width="11%" align="right" valign="top"> 22,606</td>
<td width="11%" align="right" valign="top"> 26,640</td>
</tr>
<tr>
<td width="20%" align="left" valign="top"> Morphine</td>
<td width="11%" align="right" valign="top"> 2,050,265</td>
<td width="11%" align="right" valign="top"> 2,185,490</td>
<td width="11%" align="right" valign="top"> 2,054,670</td>
<td width="11%" align="right" valign="top"> 2,115,789</td>
<td width="11%" align="right" valign="top"> 2,204,656</td>
<td width="11%" align="right" valign="top"> 2,263,405</td>
<td width="11%" align="right" valign="top"> 2,429,128</td>
</tr>
<tr>
<td width="20%" align="left" valign="top"> Morphine and cocaine with Chlorpromazine</td>
<td width="11%" align="right" valign="top"> 0</td>
<td width="11%" align="right" valign="top"> 0</td>
<td width="11%" align="right" valign="top"> 0</td>
<td width="11%" align="right" valign="top"> 0</td>
<td width="11%" align="right" valign="top"> 0</td>
<td width="11%" align="right" valign="top"> 0</td>
<td width="11%" align="right" valign="top"> 0</td>
</tr>
<tr>
<td width="20%" align="left" valign="top"> Morphine with cocaine</td>
<td width="11%" align="right" valign="top"> 0</td>
<td width="11%" align="right" valign="top"> 0</td>
<td width="11%" align="right" valign="top"> 0</td>
<td width="11%" align="right" valign="top"> 0</td>
<td width="11%" align="right" valign="top"> 0</td>
<td width="11%" align="right" valign="top"> 0</td>
<td width="11%" align="right" valign="top"> 0</td>
</tr>
<tr>
<td width="20%" align="left" valign="top"> Morphine with cyclizine</td>
<td width="11%" align="right" valign="top"> 38,316</td>
<td width="11%" align="right" valign="top"> 35,822</td>
<td width="11%" align="right" valign="top"> 34,982</td>
<td width="11%" align="right" valign="top"> 31,168</td>
<td width="11%" align="right" valign="top"> 29,474</td>
<td width="11%" align="right" valign="top"> 31,029</td>
<td width="11%" align="right" valign="top"> 29,090</td>
</tr>
<tr>
<td width="20%" align="left" valign="top"> Nalbuphine Hydrochloride</td>
<td width="11%" align="right" valign="top"> 5,272</td>
<td width="11%" align="right" valign="top"> 4,724</td>
<td width="11%" align="right" valign="top"> 5,158</td>
<td width="11%" align="right" valign="top"> 4,867</td>
<td width="11%" align="right" valign="top"> 2,218</td>
<td width="11%" align="right" valign="top"> 0</td>
<td width="11%" align="right" valign="top"> 0</td>
</tr>
<tr>
<td width="20%" align="left" valign="top"> Opium</td>
<td width="11%" align="right" valign="top"> 0</td>
<td width="11%" align="right" valign="top"> 0</td>
<td width="11%" align="right" valign="top"> 0</td>
<td width="11%" align="right" valign="top"> 0</td>
<td width="11%" align="right" valign="top"> 0</td>
<td width="11%" align="right" valign="top"> 0</td>
<td width="11%" align="right" valign="top"> 0</td>
</tr>
<tr>
<td width="20%" align="left" valign="top"> Oxycodone</td>
<td width="11%" align="right" valign="top"> 233,029</td>
<td width="11%" align="right" valign="top"> 667,080</td>
<td width="11%" align="right" valign="top"> 1,195,886</td>
<td width="11%" align="right" valign="top"> 1,876,110</td>
<td width="11%" align="right" valign="top"> 2,557,979</td>
<td width="11%" align="right" valign="top"> 3,180,230</td>
<td width="11%" align="right" valign="top"> 3,999,635</td>
</tr>
<tr>
<td width="20%" align="left" valign="top"> Paracetamol with Tramadol Hydrochloride</td>
<td width="11%" align="right" valign="top"> 0</td>
<td width="11%" align="right" valign="top"> 0</td>
<td width="11%" align="right" valign="top"> 0</td>
<td width="11%" align="right" valign="top"> 0</td>
<td width="11%" align="right" valign="top"> 64,874</td>
<td width="11%" align="right" valign="top"> 261,684</td>
<td width="11%" align="right" valign="top"> 363,871</td>
</tr>
<tr>
<td width="20%" align="left" valign="top"> Papaverine Hydrochloride</td>
<td width="11%" align="right" valign="top"> 0</td>
<td width="11%" align="right" valign="top"> 0</td>
<td width="11%" align="right" valign="top"> 0</td>
<td width="11%" align="right" valign="top"> 0</td>
<td width="11%" align="right" valign="top"> 0</td>
<td width="11%" align="right" valign="top"> 0</td>
<td width="11%" align="right" valign="top"> 0</td>
</tr>
<tr>
<td width="20%" align="left" valign="top"> Pentazocine</td>
<td width="11%" align="right" valign="top"> 37,858</td>
<td width="11%" align="right" valign="top"> 34,368</td>
<td width="11%" align="right" valign="top"> 33,029</td>
<td width="11%" align="right" valign="top"> 33,141</td>
<td width="11%" align="right" valign="top"> 26,986</td>
<td width="11%" align="right" valign="top"> 20,927</td>
<td width="11%" align="right" valign="top"> 15,231</td>
</tr>
<tr>
<td width="20%" align="left" valign="top"> Pethidine Hydrochloride</td>
<td width="11%" align="right" valign="top"> 74,880</td>
<td width="11%" align="right" valign="top"> 74,672</td>
<td width="11%" align="right" valign="top"> 72,681</td>
<td width="11%" align="right" valign="top"> 70,414</td>
<td width="11%" align="right" valign="top"> 67,613</td>
<td width="11%" align="right" valign="top"> 59,503</td>
<td width="11%" align="right" valign="top"> 60,810</td>
</tr>
<tr>
<td width="20%" align="left" valign="top"> Pethidine with Promethazine</td>
<td width="11%" align="right" valign="top"> 20</td>
<td width="11%" align="right" valign="top"> 8</td>
<td width="11%" align="right" valign="top"> 7</td>
<td width="11%" align="right" valign="top"> 1</td>
<td width="11%" align="right" valign="top"> 7</td>
<td width="11%" align="right" valign="top"> 0</td>
<td width="11%" align="right" valign="top"> 0</td>
</tr>
<tr>
<td width="20%" align="left" valign="top"> Phenazocine Hydrobromide</td>
<td width="11%" align="right" valign="top"> 12,588</td>
<td width="11%" align="right" valign="top"> 369</td>
<td width="11%" align="right" valign="top"> 0</td>
<td width="11%" align="right" valign="top"> 0</td>
<td width="11%" align="right" valign="top"> 0</td>
<td width="11%" align="right" valign="top"> 0</td>
<td width="11%" align="right" valign="top"> 0</td>
</tr>
<tr>
<td width="20%" align="left" valign="top"> Phenoperidine Hydrochloride</td>
<td width="11%" align="right" valign="top"> 0</td>
<td width="11%" align="right" valign="top"> 0</td>
<td width="11%" align="right" valign="top"> 0</td>
<td width="11%" align="right" valign="top"> 0</td>
<td width="11%" align="right" valign="top"> 0</td>
<td width="11%" align="right" valign="top"> 0</td>
<td width="11%" align="right" valign="top"> 0</td>
</tr>
<tr>
<td width="20%" height="4" align="left" valign="top"> Tramadol Hydrochloride</td>
<td width="11%" height="4" align="right" valign="top"> 7,433,484</td>
<td width="11%" height="4" align="right" valign="top"> 8,217,968</td>
<td width="11%" height="4" align="right" valign="top"> 9,174,006</td>
<td width="11%" height="4" align="right" valign="top"> 10,477,496</td>
<td width="11%" height="4" align="right" valign="top"> 11,838,371</td>
<td width="11%" height="4" align="right" valign="top"> 13,510,233</td>
<td width="11%" height="4" align="right" valign="top"> 16,393,774</td>
</tr>
<tr>
<td width="20%" align="left" valign="top"> Total</td>
<td width="11%" align="right" valign="top"> 14,866,968</td>
<td width="11%" align="right" valign="top"> 16,435,937</td>
<td width="11%" align="right" valign="top"> 18,348,012</td>
<td width="11%" align="right" valign="top"> 20,954,992</td>
<td width="11%" align="right" valign="top"> 23,676,741</td>
<td width="11%" align="right" valign="top"> 27,020,467</td>
<td width="11%" align="right" valign="top"> 32,787,549</td>
</tr>
</table></p>

  <p>The information in the table has been provided by NHS National Services Scotland.</p>

</reply>


<minor-heading id="uk.org.publicwhip/spwa/2008-03-25.S3W-10841.h" nospeaker="True" url="http://www.scottish.parliament.uk/business/pqa/wa-08/wa0325.htm#10">Medication</minor-heading>

<ques id="uk.org.publicwhip/spwa/2008-03-25.S3W-10841.q0" speakerid="uk.org.publicwhip/member/80395" speakername="Jamie Stone (Caithness, Sutherland and Easter Ross) (LD)" spid="S3W-10841" url="http://www.scottish.parliament.uk/business/pqa/wa-08/wa0325.htm#10">

  <p>To ask the Scottish Executive how many prescriptions for antidepressants have been issued through the NHS since these drugs were made available and what the total cost has been to the NHS each year, broken down by drug.</p>

</ques>


<reply id="uk.org.publicwhip/spwa/2008-03-25.S3W-10841.r0" speakerid="uk.org.publicwhip/member/80379" speakername="Shona Robison" url="http://www.scottish.parliament.uk/business/pqa/wa-08/wa0325.htm#10">

  <p>It is not possible to provide the information in the format requested. Information on antidepressant drugs prescribing by NHS Scotland is published by NHS National Services Scotland on the Scottish Health Statistics website at <a href="http://www.isdscotland.org/prescribing" target="_blank">www.isdscotland.org/prescribing</a> .</p>

  <p>Details of the prescribing of antidepressants since the financial year ending 31 March 1993 can be found at:</p>

  <p><a href="http://www.isdscotland.org/isd/information-and-statistics.jsp?pContentID=3671&amp;p_applic=CCC&amp;p_service=Content.show&amp;" target="_blank">http://www.isdscotland.org/isd/information-and-statistics.jsp?pContentID=3671&amp;p_applic=CCC&amp;p_service=Content.show&amp;</a>.</p>

  <p>The data given in table 8 of these details refer to prescriptions dispensed in the community by community pharmacists and dispensing doctors but do not include medicines dispensed in hospitals or hospital-based clinics. The cost given is that before addition of any pharmacy fees and deduction of any discount and patient charges.</p>

</reply>


<minor-heading id="uk.org.publicwhip/spwa/2008-03-25.S3W-10852.h" nospeaker="True" url="http://www.scottish.parliament.uk/business/pqa/wa-08/wa0325.htm#11">NHS Waiting Times</minor-heading>

<ques id="uk.org.publicwhip/spwa/2008-03-25.S3W-10852.q0" speakerid="uk.org.publicwhip/member/80284" speakername="Richard Baker (North East Scotland) (Lab)" spid="S3W-10852" url="http://www.scottish.parliament.uk/business/pqa/wa-08/wa0325.htm#11">

  <p>To ask the Scottish Executive how many delayed discharges there have been in (a) Grampian and (b) Tayside since 2005.</p>

</ques>


<reply id="uk.org.publicwhip/spwa/2008-03-25.S3W-10852.r0" speakerid="uk.org.publicwhip/member/80379" speakername="Shona Robison" url="http://www.scottish.parliament.uk/business/pqa/wa-08/wa0325.htm#11">

  <p>The requested information is shown in the following table:</p>

  <p>Patients Ready for Discharge</p>

  <p><table width="75%" border="BORDER" cellpadding="2" cellspacing="0" bordercolor="#CCCCCC">
<tr>
<td width="21%" valign="top" rowspan="3"> </td>
<td width="26%" colspan="2" rowspan="2" align="center" valign="top"> Scotland</td>
<td width="53%" colspan="4" align="center" valign="top"> NHS Board Area of Treatment</td>
</tr>
<tr>
<td width="28%" colspan="2" align="center" valign="top"> Grampian</td>
<td width="24%" colspan="2" align="center" valign="top"> Tayside</td>
</tr>
<tr>
<td width="17%" height="13" align="center" valign="top"> No. Outwith 6 Weeks<sup>1</sup></td>
<td width="9%" height="13" align="center" valign="top"> Total<sup>2</sup></td>
<td width="16%" height="13" align="center" valign="top"> No. Outwith 6 Weeks</td>
<td width="12%" height="13" align="center" valign="top"> Total</td>
<td width="17%" height="13" align="center" valign="top"> No. Outwith 6 Weeks</td>
<td width="8%" height="13" align="center" valign="top"> Total</td>
</tr>
<tr>
<td width="21%" align="left" valign="top"> January 2005</td>
<td width="17%" align="right" valign="top"> 959</td>
<td width="9%" align="right" valign="top"> 1,668</td>
<td width="16%" align="right" valign="top"> 151</td>
<td width="12%" align="right" valign="top"> 248</td>
<td width="17%" align="right" valign="top"> 49</td>
<td width="8%" align="right" valign="top"> 108</td>
</tr>
<tr>
<td width="21%" align="left" valign="top"> April 2005</td>
<td width="17%" align="right" valign="top"> 636</td>
<td width="9%" align="right" valign="top"> 1,332</td>
<td width="16%" align="right" valign="top"> 105</td>
<td width="12%" align="right" valign="top"> 194</td>
<td width="17%" align="right" valign="top"> 37</td>
<td width="8%" align="right" valign="top"> 99</td>
</tr>
<tr>
<td width="21%" align="left" valign="top"> July 2005</td>
<td width="17%" align="right" valign="top"> 753</td>
<td width="9%" align="right" valign="top"> 1,465</td>
<td width="16%" align="right" valign="top"> 99</td>
<td width="12%" align="right" valign="top"> 217</td>
<td width="17%" align="right" valign="top"> 56</td>
<td width="8%" align="right" valign="top"> 117</td>
</tr>
<tr>
<td width="21%" align="left" valign="top"> October 2005</td>
<td width="17%" align="right" valign="top"> 875</td>
<td width="9%" align="right" valign="top"> 1,576</td>
<td width="16%" align="right" valign="top"> 128</td>
<td width="12%" align="right" valign="top"> 211</td>
<td width="17%" align="right" valign="top"> 49</td>
<td width="8%" align="right" valign="top"> 113</td>
</tr>
<tr>
<td width="21%" align="left" valign="top"> January 2006</td>
<td width="17%" align="right" valign="top"> 778</td>
<td width="9%" align="right" valign="top"> 1,488</td>
<td width="16%" align="right" valign="top"> 146</td>
<td width="12%" align="right" valign="top"> 239</td>
<td width="17%" align="right" valign="top"> 56</td>
<td width="8%" align="right" valign="top"> 123</td>
</tr>
<tr>
<td width="21%" align="left" valign="top"> April 2006</td>
<td width="17%" align="right" valign="top"> 498</td>
<td width="9%" align="right" valign="top"> 1,046</td>
<td width="16%" align="right" valign="top"> 84</td>
<td width="12%" align="right" valign="top"> 156</td>
<td width="17%" align="right" valign="top"> 25</td>
<td width="8%" align="right" valign="top"> 77</td>
</tr>
<tr>
<td width="21%" align="left" valign="top"> July 2006</td>
<td width="17%" align="right" valign="top"> 627</td>
<td width="9%" align="right" valign="top"> 1,243</td>
<td width="16%" align="right" valign="top"> 84</td>
<td width="12%" align="right" valign="top"> 129</td>
<td width="17%" align="right" valign="top"> 52</td>
<td width="8%" align="right" valign="top"> 111</td>
</tr>
<tr>
<td width="21%" align="left" valign="top"> October 2006</td>
<td width="17%" align="right" valign="top"> 679</td>
<td width="9%" align="right" valign="top"> 1,327</td>
<td width="16%" align="right" valign="top"> 88</td>
<td width="12%" align="right" valign="top"> 156</td>
<td width="17%" align="right" valign="top"> 61</td>
<td width="8%" align="right" valign="top"> 133</td>
</tr>
<tr>
<td width="21%" align="left" valign="top"> January 2007</td>
<td width="17%" align="right" valign="top"> 606</td>
<td width="9%" align="right" valign="top"> 1,182</td>
<td width="16%" align="right" valign="top"> 95</td>
<td width="12%" align="right" valign="top"> 155</td>
<td width="17%" align="right" valign="top"> 50</td>
<td width="8%" align="right" valign="top"> 96</td>
</tr>
<tr>
<td width="21%" align="left" valign="top"> April 2007</td>
<td width="17%" align="right" valign="top"> 233</td>
<td width="9%" align="right" valign="top"> 755</td>
<td width="16%" align="right" valign="top"> 34</td>
<td width="12%" align="right" valign="top"> 102</td>
<td width="17%" align="right" valign="top"> 9</td>
<td width="8%" align="right" valign="top"> 48</td>
</tr>
<tr>
<td width="21%" align="left" valign="top"> July 2007</td>
<td width="17%" align="right" valign="top"> 423</td>
<td width="9%" align="right" valign="top"> 1,031</td>
<td width="16%" align="right" valign="top"> 43</td>
<td width="12%" align="right" valign="top"> 109</td>
<td width="17%" align="right" valign="top"> 42</td>
<td width="8%" align="right" valign="top"> 101</td>
</tr>
<tr>
<td width="21%" align="left" valign="top"> October 2007</td>
<td width="17%" align="right" valign="top"> 425</td>
<td width="9%" align="right" valign="top"> 1,008</td>
<td width="16%" align="right" valign="top"> 48</td>
<td width="12%" align="right" valign="top"> 116</td>
<td width="17%" align="right" valign="top"> 49</td>
<td width="8%" align="right" valign="top"> 125</td>
</tr>
<tr>
<td width="21%" align="left" valign="top"> January 2008</td>
<td width="17%" align="right" valign="top"> 316</td>
<td width="9%" align="right" valign="top"> 824</td>
<td width="16%" align="right" valign="top"> 63</td>
<td width="12%" align="right" valign="top"> 107</td>
<td width="17%" align="right" valign="top"> 17</td>
<td width="8%" align="right" valign="top"> 67</td>
</tr>
</table></p>

  <p>Source: ISD Scotland, Ref: IRS2008-00691.</p>

  <p>Notes:</p>

  <p>1. Number of patients ready for discharge with a duration of over six weeks (43 days or more), i.e. the common period for discharge planning agreement timescales across Scotland.</p>

  <p>2. Total number of Delayed Discharges, in all specialties.</p>

</reply>


<minor-heading id="uk.org.publicwhip/spwa/2008-03-25.S3W-10797.h" nospeaker="True" url="http://www.scottish.parliament.uk/business/pqa/wa-08/wa0325.htm#12">Non-Profit Distributing Model</minor-heading>

<ques id="uk.org.publicwhip/spwa/2008-03-25.S3W-10797.q0" speakerid="uk.org.publicwhip/member/80378" speakername="Jeremy Purvis (Tweeddale, Ettrick and Lauderdale) (LD)" spid="S3W-10797" url="http://www.scottish.parliament.uk/business/pqa/wa-08/wa0325.htm#12">

  <p>To ask the Scottish Executive how many projects in Scotland have been developed using the non-profit distributing model.</p>

</ques>


<reply id="uk.org.publicwhip/spwa/2008-03-25.S3W-10797.r0" speakerid="uk.org.publicwhip/member/80397" speakername="John Swinney" url="http://www.scottish.parliament.uk/business/pqa/wa-08/wa0325.htm#12">

  <p>There have been three projects in Scotland completed using the non-profit distributing (NPD) model. These projects are in the schools sector and are now in construction. There are also a further four projects at various stages of procurement currently using the NPD model, or a variation. Three of these are in the schools sector with the other one being in health. We have recently announced that the Borders rail project will be procured using the NPD model. In addition, major rail public transport infrastructure is delivered through Network Rail Regulatory Asset base, which follows NPD principles.</p>

</reply>


<minor-heading id="uk.org.publicwhip/spwa/2008-03-25.S3W-10813.h" nospeaker="True" url="http://www.scottish.parliament.uk/business/pqa/wa-08/wa0325.htm#13">Planning</minor-heading>

<ques id="uk.org.publicwhip/spwa/2008-03-25.S3W-10813.q0" speakerid="uk.org.publicwhip/member/80328" speakername="Jamie Hepburn (Central Scotland) (SNP)" spid="S3W-10813" url="http://www.scottish.parliament.uk/business/pqa/wa-08/wa0325.htm#13">

  <p>To ask the Scottish Executive how many renewable energy development planning applications have been called in by Scottish ministers in each year since 1999, broken down by type of development.</p>

</ques>


<reply id="uk.org.publicwhip/spwa/2008-03-25.S3W-10813.r0" speakerid="uk.org.publicwhip/member/80393" speakername="Stewart Stevenson" url="http://www.scottish.parliament.uk/business/pqa/wa-08/wa0325.htm#13">

  <p>The information requested is provided in the following table:</p>

  <p><table width="50%" border="BORDER" cellpadding="2" cellspacing="0" bordercolor="#CCCCCC">
<tr>
<td width="14%" align="left" valign="top"> Year</td>
<td width="44%" align="center" valign="top"> Applications Called In</td>
<td width="43%" align="center" valign="top"> Type of development</td>
</tr>
<tr>
<td width="14%" align="left" valign="top"> 1999</td>
<td width="44%" align="right" valign="top"> 0</td>
<td width="43%" align="left" valign="top"> -</td>
</tr>
<tr>
<td width="14%" align="left" valign="top"> 2000</td>
<td width="44%" align="right" valign="top"> 0</td>
<td width="43%" align="left" valign="top"> -</td>
</tr>
<tr>
<td width="14%" align="left" valign="top"> 2001</td>
<td width="44%" align="right" valign="top"> 1</td>
<td width="43%" align="left" valign="top"> Wind power</td>
</tr>
<tr>
<td width="14%" align="left" valign="top"> 2002</td>
<td width="44%" align="right" valign="top"> 1</td>
<td width="43%" align="left" valign="top"> Wind power</td>
</tr>
<tr>
<td width="14%" align="left" valign="top"> 2003</td>
<td width="44%" align="right" valign="top"> 0</td>
<td width="43%" align="left" valign="top"> -</td>
</tr>
<tr>
<td width="14%" align="left" valign="top"> 2004</td>
<td width="44%" align="right" valign="top"> 2</td>
<td width="43%" align="left" valign="top"> Wind power</td>
</tr>
<tr>
<td width="14%" align="left" valign="top"> 2005</td>
<td width="44%" align="right" valign="top"> 0</td>
<td width="43%" align="left" valign="top"> -</td>
</tr>
<tr>
<td width="14%" align="left" valign="top"> 2006</td>
<td width="44%" align="right" valign="top"> 2</td>
<td width="43%" align="left" valign="top"> Wind power</td>
</tr>
<tr>
<td width="14%" align="left" valign="top"> 2007</td>
<td width="44%" align="right" valign="top"> 2</td>
<td width="43%" align="left" valign="top"> Wind power</td>
</tr>
<tr>
<td width="14%" align="left" valign="top"> 2008</td>
<td width="44%" align="right" valign="top"> 1</td>
<td width="43%" align="left" valign="top"> Wind power</td>
</tr>
</table></p>

</reply>


<minor-heading id="uk.org.publicwhip/spwa/2008-03-25.S3W-10779.h" nospeaker="True" url="http://www.scottish.parliament.uk/business/pqa/wa-08/wa0325.htm#14">Rail Network</minor-heading>

<ques id="uk.org.publicwhip/spwa/2008-03-25.S3W-10779.q0" speakerid="uk.org.publicwhip/member/80378" speakername="Jeremy Purvis (Tweeddale, Ettrick and Lauderdale) (LD)" spid="S3W-10779" url="http://www.scottish.parliament.uk/business/pqa/wa-08/wa0325.htm#14">

  <p>To ask the Scottish Executive what proportion of the construction costs of the Borders rail project will be funded through the Scottish Futures Trust or the proposed new non-profit distributing model.</p>

</ques>


<reply id="uk.org.publicwhip/spwa/2008-03-25.S3W-10779.r0" speakerid="uk.org.publicwhip/member/80393" speakername="Stewart Stevenson" url="http://www.scottish.parliament.uk/business/pqa/wa-08/wa0325.htm#14">

  <p>Exact details of what proportion of the construction costs of the Borders rail project will be funded through the proposed non-profit distributing model will be the subject of negotiations with the successful tender but is expected to be between the range of &pound;235 million and &pound;295 million as answered in my statement to Parliament on 5 March 2008.</p>

</reply>


<minor-heading id="uk.org.publicwhip/spwa/2008-03-25.S3W-10781.h" nospeaker="True" url="http://www.scottish.parliament.uk/business/pqa/wa-08/wa0325.htm#14">Rail Network</minor-heading>

<ques id="uk.org.publicwhip/spwa/2008-03-25.S3W-10781.q0" speakerid="uk.org.publicwhip/member/80378" speakername="Jeremy Purvis (Tweeddale, Ettrick and Lauderdale) (LD)" spid="S3W-10781" url="http://www.scottish.parliament.uk/business/pqa/wa-08/wa0325.htm#14">

  <p>To ask the Scottish Executive what formal contact with Partnerships UK has taken place regarding the funding of the Borders rail project and when this contact was.</p>

</ques>


<ques id="uk.org.publicwhip/spwa/2008-03-25.S3W-10801.q1" speakerid="uk.org.publicwhip/member/80378" speakername="Jeremy Purvis (Tweeddale, Ettrick and Lauderdale) (LD)" spid="S3W-10801" url="http://www.scottish.parliament.uk/business/pqa/wa-08/wa0325.htm#14">

  <p>To ask the Scottish Executive what discussions it has had with (a) Transport Scotland, (b) Partnerships UK and (c) the Waverley Railway Partnership regarding the funding of the Borders rail project through the non-profit distributing model.</p>

</ques>


<reply id="uk.org.publicwhip/spwa/2008-03-25.S3W-10801.r0" speakerid="uk.org.publicwhip/member/80393" speakername="Stewart Stevenson" url="http://www.scottish.parliament.uk/business/pqa/wa-08/wa0325.htm#14">

  <p>Transport Scotland has been in regular discussions with Partnerships UK (PUK) over funding of a number of our road and rail projects (including Borders), as recently as the day of my announcement. Transport Scotland are being advised by Ernst and Young on the Borders rail project and PUK are being engaged in the next phase of the pre-procurement development as per my announcement to Parliament last week.</p>

</reply>


<minor-heading id="uk.org.publicwhip/spwa/2008-03-25.S3W-10783.h" nospeaker="True" url="http://www.scottish.parliament.uk/business/pqa/wa-08/wa0325.htm#14">Rail Network</minor-heading>

<ques id="uk.org.publicwhip/spwa/2008-03-25.S3W-10783.q0" speakerid="uk.org.publicwhip/member/80378" speakername="Jeremy Purvis (Tweeddale, Ettrick and Lauderdale) (LD)" spid="S3W-10783" url="http://www.scottish.parliament.uk/business/pqa/wa-08/wa0325.htm#14">

  <p>To ask the Scottish Executive when the non-profit distributing model to fund the Borders rail project will be established.</p>

</ques>


<reply id="uk.org.publicwhip/spwa/2008-03-25.S3W-10783.r0" speakerid="uk.org.publicwhip/member/80393" speakername="Stewart Stevenson" url="http://www.scottish.parliament.uk/business/pqa/wa-08/wa0325.htm#14">

  <p>The non-profit distributing model to fund the Borders rail project will be established on award of tender.</p>

</reply>


<minor-heading id="uk.org.publicwhip/spwa/2008-03-25.S3W-10784.h" nospeaker="True" url="http://www.scottish.parliament.uk/business/pqa/wa-08/wa0325.htm#14">Rail Network</minor-heading>

<ques id="uk.org.publicwhip/spwa/2008-03-25.S3W-10784.q0" speakerid="uk.org.publicwhip/member/80378" speakername="Jeremy Purvis (Tweeddale, Ettrick and Lauderdale) (LD)" spid="S3W-10784" url="http://www.scottish.parliament.uk/business/pqa/wa-08/wa0325.htm#14">

  <p>To ask the Scottish Executive whether it will underwrite the construction costs of the Borders rail project.</p>

</ques>


<reply id="uk.org.publicwhip/spwa/2008-03-25.S3W-10784.r0" speakerid="uk.org.publicwhip/member/80393" speakername="Stewart Stevenson" url="http://www.scottish.parliament.uk/business/pqa/wa-08/wa0325.htm#14">

  <p>Construction costs are borne by the non-profit distributing (NPD) company which in turn receive Unitary Charge payments over the lifetime of the contract.</p>

</reply>


<minor-heading id="uk.org.publicwhip/spwa/2008-03-25.S3W-10785.h" nospeaker="True" url="http://www.scottish.parliament.uk/business/pqa/wa-08/wa0325.htm#14">Rail Network</minor-heading>

<ques id="uk.org.publicwhip/spwa/2008-03-25.S3W-10785.q0" speakerid="uk.org.publicwhip/member/80378" speakername="Jeremy Purvis (Tweeddale, Ettrick and Lauderdale) (LD)" spid="S3W-10785" url="http://www.scottish.parliament.uk/business/pqa/wa-08/wa0325.htm#14">

  <p>To ask the Scottish Executive whether all the construction costs of the Borders rail project will be required to be met before the construction of the line commences.</p>

</ques>


<reply id="uk.org.publicwhip/spwa/2008-03-25.S3W-10785.r0" speakerid="uk.org.publicwhip/member/80393" speakername="Stewart Stevenson" url="http://www.scottish.parliament.uk/business/pqa/wa-08/wa0325.htm#14">

  <p>The terms and conditions of the Borders rail project will be required to be met by the successful tenderer before the construction of the line commences.</p>

</reply>


<minor-heading id="uk.org.publicwhip/spwa/2008-03-25.S3W-10788.h" nospeaker="True" url="http://www.scottish.parliament.uk/business/pqa/wa-08/wa0325.htm#14">Rail Network</minor-heading>

<ques id="uk.org.publicwhip/spwa/2008-03-25.S3W-10788.q0" speakerid="uk.org.publicwhip/member/80378" speakername="Jeremy Purvis (Tweeddale, Ettrick and Lauderdale) (LD)" spid="S3W-10788" url="http://www.scottish.parliament.uk/business/pqa/wa-08/wa0325.htm#14">

  <p>To ask the Scottish Executive what the target date is for the design stage of the Borders rail project to be completed.</p>

</ques>


<reply id="uk.org.publicwhip/spwa/2008-03-25.S3W-10788.r0" speakerid="uk.org.publicwhip/member/80393" speakername="Stewart Stevenson" url="http://www.scottish.parliament.uk/business/pqa/wa-08/wa0325.htm#14">

  <p>The current target date for the outline specimen design stage of the Borders rail project to be completed is mid-October 2008. Final design will be the responsibility of the winning contractor/concessionary vehicle.</p>

</reply>


<minor-heading id="uk.org.publicwhip/spwa/2008-03-25.S3W-10790.h" nospeaker="True" url="http://www.scottish.parliament.uk/business/pqa/wa-08/wa0325.htm#14">Rail Network</minor-heading>

<ques id="uk.org.publicwhip/spwa/2008-03-25.S3W-10790.q0" speakerid="uk.org.publicwhip/member/80378" speakername="Jeremy Purvis (Tweeddale, Ettrick and Lauderdale) (LD)" spid="S3W-10790" url="http://www.scottish.parliament.uk/business/pqa/wa-08/wa0325.htm#14">

  <p>To ask the Scottish Executive what the target date is for the construction of the Borders rail project to be completed.</p>

</ques>


<reply id="uk.org.publicwhip/spwa/2008-03-25.S3W-10790.r0" speakerid="uk.org.publicwhip/member/80393" speakername="Stewart Stevenson" url="http://www.scottish.parliament.uk/business/pqa/wa-08/wa0325.htm#14">

  <p>As announced in my statement to Parliament on 5 March 2008, the target date for the construction of the Borders rail project to be completed is anticipated to be 2013.</p>

</reply>


<minor-heading id="uk.org.publicwhip/spwa/2008-03-25.S3W-10791.h" nospeaker="True" url="http://www.scottish.parliament.uk/business/pqa/wa-08/wa0325.htm#14">Rail Network</minor-heading>

<ques id="uk.org.publicwhip/spwa/2008-03-25.S3W-10791.q0" speakerid="uk.org.publicwhip/member/80378" speakername="Jeremy Purvis (Tweeddale, Ettrick and Lauderdale) (LD)" spid="S3W-10791" url="http://www.scottish.parliament.uk/business/pqa/wa-08/wa0325.htm#14">

  <p>To ask the Scottish Executive what the target date is for the opening of the Borders rail line.</p>

</ques>


<reply id="uk.org.publicwhip/spwa/2008-03-25.S3W-10791.r0" speakerid="uk.org.publicwhip/member/80393" speakername="Stewart Stevenson" url="http://www.scottish.parliament.uk/business/pqa/wa-08/wa0325.htm#14">

  <p>The target date for the opening of the Borders rail line will be immediately after the construction is completed and the testing and commissioning has taken place, which is currently scheduled for 2013.</p>

</reply>


<minor-heading id="uk.org.publicwhip/spwa/2008-03-25.S3W-10792.h" nospeaker="True" url="http://www.scottish.parliament.uk/business/pqa/wa-08/wa0325.htm#14">Rail Network</minor-heading>

<ques id="uk.org.publicwhip/spwa/2008-03-25.S3W-10792.q0" speakerid="uk.org.publicwhip/member/80378" speakername="Jeremy Purvis (Tweeddale, Ettrick and Lauderdale) (LD)" spid="S3W-10792" url="http://www.scottish.parliament.uk/business/pqa/wa-08/wa0325.htm#14">

  <p>To ask the Scottish Executive whether, in relation to the funding of the Borders rail project, it has any concerns that the financial market will be cautious about investing in an unproven delivery model.</p>

</ques>


<reply id="uk.org.publicwhip/spwa/2008-03-25.S3W-10792.r0" speakerid="uk.org.publicwhip/member/80393" speakername="Stewart Stevenson" url="http://www.scottish.parliament.uk/business/pqa/wa-08/wa0325.htm#14">

  <p>In the current testing financial times, investors will move to high-quality investments. Financial markets are already expressing considerable interest in providing funding via this excellent investment opportunity.</p>

</reply>


<minor-heading id="uk.org.publicwhip/spwa/2008-03-25.S3W-10793.h" nospeaker="True" url="http://www.scottish.parliament.uk/business/pqa/wa-08/wa0325.htm#14">Rail Network</minor-heading>

<ques id="uk.org.publicwhip/spwa/2008-03-25.S3W-10793.q0" speakerid="uk.org.publicwhip/member/80378" speakername="Jeremy Purvis (Tweeddale, Ettrick and Lauderdale) (LD)" spid="S3W-10793" url="http://www.scottish.parliament.uk/business/pqa/wa-08/wa0325.htm#14">

  <p>To ask the Scottish Executive how, in relation to the funding of the Borders rail project, it will attract investment into the non-profit distributing model.</p>

</ques>


<reply id="uk.org.publicwhip/spwa/2008-03-25.S3W-10793.r0" speakerid="uk.org.publicwhip/member/80393" speakername="Stewart Stevenson" url="http://www.scottish.parliament.uk/business/pqa/wa-08/wa0325.htm#14">

  <p>Established markets exist for both senior and junior debt. The procurement process will allow for thorough dialogue with lenders.</p>

</reply>


<minor-heading id="uk.org.publicwhip/spwa/2008-03-25.S3W-10796.h" nospeaker="True" url="http://www.scottish.parliament.uk/business/pqa/wa-08/wa0325.htm#14">Rail Network</minor-heading>

<ques id="uk.org.publicwhip/spwa/2008-03-25.S3W-10796.q0" speakerid="uk.org.publicwhip/member/80378" speakername="Jeremy Purvis (Tweeddale, Ettrick and Lauderdale) (LD)" spid="S3W-10796" url="http://www.scottish.parliament.uk/business/pqa/wa-08/wa0325.htm#14">

  <p>To ask the Scottish Executive over what proportion of the asset life of the Borders rail project the project capital will be repaid by annual service charges.</p>

</ques>


<reply id="uk.org.publicwhip/spwa/2008-03-25.S3W-10796.r0" speakerid="uk.org.publicwhip/member/80393" speakername="Stewart Stevenson" url="http://www.scottish.parliament.uk/business/pqa/wa-08/wa0325.htm#14">

  <p>We would expect repayment of debt to take place over 25 to 30 years</p>

</reply>


<minor-heading id="uk.org.publicwhip/spwa/2008-03-25.S3W-10800.h" nospeaker="True" url="http://www.scottish.parliament.uk/business/pqa/wa-08/wa0325.htm#14">Rail Network</minor-heading>

<ques id="uk.org.publicwhip/spwa/2008-03-25.S3W-10800.q0" speakerid="uk.org.publicwhip/member/80378" speakername="Jeremy Purvis (Tweeddale, Ettrick and Lauderdale) (LD)" spid="S3W-10800" url="http://www.scottish.parliament.uk/business/pqa/wa-08/wa0325.htm#14">

  <p>To ask the Scottish Executive why it considers that the non-profit distributing model is better suited to the Borders rail project than the Edinburgh tram scheme.</p>

</ques>


<reply id="uk.org.publicwhip/spwa/2008-03-25.S3W-10800.r0" speakerid="uk.org.publicwhip/member/80393" speakername="Stewart Stevenson" url="http://www.scottish.parliament.uk/business/pqa/wa-08/wa0325.htm#14">

  <p>The use of the Regulated Asset Base (RAB) or non-profit distribution (NPD) funding models offer maximum value for money and flexibility for projects of this nature. The procurement route chosen for the Edinburgh tram project is a matter for Edinburgh City Council.</p>

</reply>


<minor-heading id="uk.org.publicwhip/spwa/2008-03-25.S3W-10802.h" nospeaker="True" url="http://www.scottish.parliament.uk/business/pqa/wa-08/wa0325.htm#14">Rail Network</minor-heading>

<ques id="uk.org.publicwhip/spwa/2008-03-25.S3W-10802.q0" speakerid="uk.org.publicwhip/member/80378" speakername="Jeremy Purvis (Tweeddale, Ettrick and Lauderdale) (LD)" spid="S3W-10802" url="http://www.scottish.parliament.uk/business/pqa/wa-08/wa0325.htm#14">

  <p>To ask the Scottish Executive when the first statutory package consisting of physical works and land and statutory powers authorised under the Waverley Railway (Scotland) Act 2006 will commence.</p>

</ques>


<reply id="uk.org.publicwhip/spwa/2008-03-25.S3W-10802.r0" speakerid="uk.org.publicwhip/member/80393" speakername="Stewart Stevenson" url="http://www.scottish.parliament.uk/business/pqa/wa-08/wa0325.htm#14">

  <p>The first statutory package will commence at the start of the construction phase of the project, currently expected to be 2011.</p>

</reply>


<minor-heading id="uk.org.publicwhip/spwa/2008-03-25.S3W-10908.h" nospeaker="True" url="http://www.scottish.parliament.uk/business/pqa/wa-08/wa0325.htm#15">Road Accidents</minor-heading>

<ques id="uk.org.publicwhip/spwa/2008-03-25.S3W-10908.q0" speakerid="uk.org.publicwhip/member/80389" speakername="Margaret Smith (Edinburgh West) (LD)" spid="S3W-10908" url="http://www.scottish.parliament.uk/business/pqa/wa-08/wa0325.htm#15">

  <p>To ask the Scottish Executive whether it will collate statistics on road accidents involving (a) ambulance and (b) fire and rescue service vehicles, broken down by the number of (i) deaths and (ii) serious injuries resulting from such accidents.</p>

</ques>


<reply id="uk.org.publicwhip/spwa/2008-03-25.S3W-10908.r0" speakerid="uk.org.publicwhip/member/80393" speakername="Stewart Stevenson" url="http://www.scottish.parliament.uk/business/pqa/wa-08/wa0325.htm#15">

  <p>The Scottish Government has no immediate plans to collate statistics which specifically identify road accidents involving ambulance and fire rescue vehicles. However, the impending GB-wide review of road accident statistics will include a public consultation, and all responses will be considered.</p>

  <p>Statistics on the number of accidents involving fire service and ambulance vehicles are available separately from Her Majesty&rsquo;s Chief Inspector of Fire Services for Scotland and the Scottish Ambulance Service.</p>

</reply>


<minor-heading id="uk.org.publicwhip/spwa/2008-03-25.S3W-10827.h" nospeaker="True" url="http://www.scottish.parliament.uk/business/pqa/wa-08/wa0325.htm#16">Roads</minor-heading>

<ques id="uk.org.publicwhip/spwa/2008-03-25.S3W-10827.q0" speakerid="uk.org.publicwhip/member/80284" speakername="Richard Baker (North East Scotland) (Lab)" spid="S3W-10827" url="http://www.scottish.parliament.uk/business/pqa/wa-08/wa0325.htm#16">

  <p>To ask the Scottish Executive how much funding was spent on roadworks in Grampian during (a) 2002-03, (b) 2003-04, (c) 2004-05, (d) 2005-06, (e) 2006-07 and (f) 2007-08.</p>

</ques>


<reply id="uk.org.publicwhip/spwa/2008-03-25.S3W-10827.r0" speakerid="uk.org.publicwhip/member/80393" speakername="Stewart Stevenson" url="http://www.scottish.parliament.uk/business/pqa/wa-08/wa0325.htm#16">

  <p>The following table provides net revenue expenditure on local road maintenance in the Aberdeen, Aberdeenshire and Moray Council areas as requested to the year 2006-07 and trunk road spend to date by the north east unit of Transport Scotland, which includes the former Grampian Regional Council area.</p>

  <p>Net Revenue Expenditure on Road Maintenance<sup>1,2 </sup>(&pound;000)</p>

  <p><table width="75%" border="BORDER" cellpadding="2" cellspacing="0" bordercolor="#CCCCCC">
<tr>
<td width="39%" valign="top"> </td>
<td width="10%" align="center" valign="top"> 2002-03</td>
<td width="10%" align="center" valign="top"> 2003-04</td>
<td width="10%" align="center" valign="top"> 2004-05</td>
<td width="10%" align="center" valign="top"> 2005-06</td>
<td width="10%" align="center" valign="top"> 2006-07</td>
<td width="10%" align="center" valign="top"> 2007-08</td>
</tr>
<tr>
<td width="39%" align="left" valign="top"> Aberdeen City<strong><sup>a</sup></strong></td>
<td width="10%" align="right" valign="top"> 6,819</td>
<td width="10%" align="right" valign="top"> 8,089</td>
<td width="10%" align="right" valign="top"> 7,927</td>
<td width="10%" align="right" valign="top"> 8,630</td>
<td width="10%" align="right" valign="top"> 7,278</td>
<td width="10%" align="right" valign="top"> N/A</td>
</tr>
<tr>
<td width="39%" align="left" valign="top"> Aberdeenshire<strong><sup>a</sup></strong></td>
<td width="10%" align="right" valign="top"> 18,476</td>
<td width="10%" align="right" valign="top"> 19,880</td>
<td width="10%" align="right" valign="top"> 18,451</td>
<td width="10%" align="right" valign="top"> 18,296</td>
<td width="10%" align="right" valign="top"> 15,106</td>
<td width="10%" align="right" valign="top"> N/A</td>
</tr>
<tr>
<td width="39%" align="left" valign="top"> Moray<strong><sup>a</sup></strong></td>
<td width="10%" align="right" valign="top"> 6,158</td>
<td width="10%" align="right" valign="top"> 6,496</td>
<td width="10%" align="right" valign="top"> 7,912</td>
<td width="10%" align="right" valign="top"> 7,184</td>
<td width="10%" align="right" valign="top"> 6,641</td>
<td width="10%" align="right" valign="top"> N/A</td>
</tr>
<tr>
<td width="39%" align="left" valign="top"> North East Unit, Transport Scotland<strong><sup>b</sup></strong></td>
<td width="10%" align="right" valign="top"> 22,698</td>
<td width="10%" align="right" valign="top"> 17,052</td>
<td width="10%" align="right" valign="top"> 30,824</td>
<td width="10%" align="right" valign="top"> 28,699</td>
<td width="10%" align="right" valign="top"> 30,051</td>
<td width="10%" align="right" valign="top"> 20,555</td>
</tr>
</table></p>

  <p>Source:</p>

  <p>a. Scottish Local Government Financial Statistics publications.</p>

  <p>b. Transport Scotland.</p>

  <p>Notes:</p>

  <p>1. Net expenditure financed from grants, non domestic rates, council taxes and balances.</p>

  <p>2. Includes expenditure on winter maintenance and structural, environmental and safety maintenance and routine repairs.</p>

</reply>


<minor-heading id="uk.org.publicwhip/spwa/2008-03-25.S3W-10855.h" nospeaker="True" url="http://www.scottish.parliament.uk/business/pqa/wa-08/wa0325.htm#16">Roads</minor-heading>

<ques id="uk.org.publicwhip/spwa/2008-03-25.S3W-10855.q0" speakerid="uk.org.publicwhip/member/80354" speakername="Jamie McGrigor (Highlands and Islands) (Con)" spid="S3W-10855" url="http://www.scottish.parliament.uk/business/pqa/wa-08/wa0325.htm#16">

  <p>To ask the Scottish Executive whether the &pound;16 million of improvement schemes identified in the A82 Tarbet to Fort William Route Action Plan of February 2006, namely Pulpit Rock, the Crianlarich bypass and the online improvements at Inveruglas and south of Inverarnan, are still on schedule to be constructed by 2012.</p>

</ques>


<reply id="uk.org.publicwhip/spwa/2008-03-25.S3W-10855.r0" speakerid="uk.org.publicwhip/member/80393" speakername="Stewart Stevenson" url="http://www.scottish.parliament.uk/business/pqa/wa-08/wa0325.htm#16">

  <p>Transport Scotland is progressing with the improvement work at Pulpit Rock and a bypass of Crianlarich which subject to the completion of statutory procedures, remain on course to be delivered within the current programme to 2012.</p>

  <p>Feasibility studies for schemes at Inveruglas and south of Inverarnan are currently being investigated. Depending on the outcome of this preliminary work, and value for money being demonstrated, we are aiming to take the development of the schemes forward to preliminary assessment and detailed design, publication of statutory procedures and completion of the design within a four-year timescale. Construction thereafter will depend on the availability of finance at the time.</p>

</reply>


<minor-heading id="uk.org.publicwhip/spwa/2008-03-25.S3W-10856.h" nospeaker="True" url="http://www.scottish.parliament.uk/business/pqa/wa-08/wa0325.htm#16">Roads</minor-heading>

<ques id="uk.org.publicwhip/spwa/2008-03-25.S3W-10856.q0" speakerid="uk.org.publicwhip/member/80363" speakername="Des McNulty (Clydebank and Milngavie) (Lab)" spid="S3W-10856" url="http://www.scottish.parliament.uk/business/pqa/wa-08/wa0325.htm#16">

  <p>To ask the Scottish Executive whether it is planned to take forward the Aberdeen Western Peripheral Route as a PPP to allow the costs to be spread over the longer term and, if not, what funding option is currently favoured.</p>

</ques>


<reply id="uk.org.publicwhip/spwa/2008-03-25.S3W-10856.r0" speakerid="uk.org.publicwhip/member/80393" speakername="Stewart Stevenson" url="http://www.scottish.parliament.uk/business/pqa/wa-08/wa0325.htm#16">

  <p>I refer the member to the answer to question S3O-656 on 20 September 2007. All answers to oral parliamentary questions are available on the Official Reports in the Parliament&rsquo;s website <a href="../../../business/officialReports/meetingsParliament/or-07/sor0920-02.htm#Col1963">http://www.scottish.parliament.uk/business/officialReports/meetingsParliament/or-07/sor0920-02.htm#Col1963</a> .</p>

</reply>


<minor-heading id="uk.org.publicwhip/spwa/2008-03-25.S3W-10857.h" nospeaker="True" url="http://www.scottish.parliament.uk/business/pqa/wa-08/wa0325.htm#16">Roads</minor-heading>

<ques id="uk.org.publicwhip/spwa/2008-03-25.S3W-10857.q0" speakerid="uk.org.publicwhip/member/80363" speakername="Des McNulty (Clydebank and Milngavie) (Lab)" spid="S3W-10857" url="http://www.scottish.parliament.uk/business/pqa/wa-08/wa0325.htm#16">

  <p>To ask the Scottish Executive what the costs were of detailed design and value engineering work on the Murtle option for the Aberdeen Western Peripheral Route; what reductions in cost were secured through this work, and whether any of this work will provide any benefit following the decision not to proceed with the Murtle option.</p>

</ques>


<reply id="uk.org.publicwhip/spwa/2008-03-25.S3W-10857.r0" speakerid="uk.org.publicwhip/member/80393" speakername="Stewart Stevenson" url="http://www.scottish.parliament.uk/business/pqa/wa-08/wa0325.htm#16">

  <p>Prior to the announcement in December 2005 of the adoption of the Milltimber Brae and Fastlink, &pound;12.2 million was spent on the design of the Murtle Route. &pound;6.4 million of the &pound;12.2 million spent related to sections of the Murtle route common to the current proposals.</p>

</reply>


<minor-heading id="uk.org.publicwhip/spwa/2008-03-25.S3W-10858.h" nospeaker="True" url="http://www.scottish.parliament.uk/business/pqa/wa-08/wa0325.htm#16">Roads</minor-heading>

<ques id="uk.org.publicwhip/spwa/2008-03-25.S3W-10858.q0" speakerid="uk.org.publicwhip/member/80363" speakername="Des McNulty (Clydebank and Milngavie) (Lab)" spid="S3W-10858" url="http://www.scottish.parliament.uk/business/pqa/wa-08/wa0325.htm#16">

  <p>To ask the Scottish Executive whether, in relation to the Aberdeen Western Peripheral Route, any calculations were made of the economic, social and transport advantages and disadvantages of options closer to Aberdeen city centre compared with the Milltimber option and whether it will list any such calculations, broken down by option.</p>

</ques>


<reply id="uk.org.publicwhip/spwa/2008-03-25.S3W-10858.r0" speakerid="uk.org.publicwhip/member/80393" speakername="Stewart Stevenson" url="http://www.scottish.parliament.uk/business/pqa/wa-08/wa0325.htm#16">

  <p>Details of the economic, social and transport advantages and disadvantages on all considered options can be found in the STAG assessments which have been published on the project website. ( <a href="http://www.awpr.co.uk" target="_blank">www.awpr.co.uk</a> ).</p>

</reply>


<minor-heading id="uk.org.publicwhip/spwa/2008-03-25.S3W-10860.h" nospeaker="True" url="http://www.scottish.parliament.uk/business/pqa/wa-08/wa0325.htm#16">Roads</minor-heading>

<ques id="uk.org.publicwhip/spwa/2008-03-25.S3W-10860.q0" speakerid="uk.org.publicwhip/member/80363" speakername="Des McNulty (Clydebank and Milngavie) (Lab)" spid="S3W-10860" url="http://www.scottish.parliament.uk/business/pqa/wa-08/wa0325.htm#16">

  <p>To ask the Scottish Executive what estimate it has made of the additional cost of proceeding with the Milltimber option for the Aberdeen Western Peripheral Route compared with the Murtle option favoured by Aberdeen City and Aberdeenshire councils.</p>

</ques>


<reply id="uk.org.publicwhip/spwa/2008-03-25.S3W-10860.r0" speakerid="uk.org.publicwhip/member/80393" speakername="Stewart Stevenson" url="http://www.scottish.parliament.uk/business/pqa/wa-08/wa0325.htm#16">

  <p>I refer the member to the answer to question S3W-2518 on 23 August 2007. All answers to written parliamentary questions are available on the Parliament&rsquo;s website, the search facility for which can be found at <a href="../../../webapp/wa.search">http://www.scottish.parliament.uk/webapp/wa.search</a> .</p>

</reply>


<minor-heading id="uk.org.publicwhip/spwa/2008-03-25.S3W-10870.h" nospeaker="True" url="http://www.scottish.parliament.uk/business/pqa/wa-08/wa0325.htm#17">Sexual Health</minor-heading>

<ques id="uk.org.publicwhip/spwa/2008-03-25.S3W-10870.q0" speakerid="uk.org.publicwhip/member/80295" speakername="Jackson Carlaw (West of Scotland) (Con)" spid="S3W-10870" url="http://www.scottish.parliament.uk/business/pqa/wa-08/wa0325.htm#17">

  <p>To ask the Scottish Executive whether it intends to introduce a national screening programme for chlamydia.</p>

</ques>


<reply id="uk.org.publicwhip/spwa/2008-03-25.S3W-10870.r0" speakerid="uk.org.publicwhip/member/80379" speakername="Shona Robison" url="http://www.scottish.parliament.uk/business/pqa/wa-08/wa0325.htm#17">

  <p>No. Chlamydia testing in Scotland takes place on an opportunistic basis by GPs and other health care professionals, which is in line with the SIGN guidelines.</p>

</reply>


<minor-heading id="uk.org.publicwhip/spwa/2008-03-25.S3W-10871.h" nospeaker="True" url="http://www.scottish.parliament.uk/business/pqa/wa-08/wa0325.htm#17">Sexual Health</minor-heading>

<ques id="uk.org.publicwhip/spwa/2008-03-25.S3W-10871.q0" speakerid="uk.org.publicwhip/member/80295" speakername="Jackson Carlaw (West of Scotland) (Con)" spid="S3W-10871" url="http://www.scottish.parliament.uk/business/pqa/wa-08/wa0325.htm#17">

  <p>To ask the Scottish Executive how many diagnoses of chlamydia were reported to Health Protection Scotland in the third quarter of 2007-08.</p>

</ques>


<reply id="uk.org.publicwhip/spwa/2008-03-25.S3W-10871.r0" speakerid="uk.org.publicwhip/member/80379" speakername="Shona Robison" url="http://www.scottish.parliament.uk/business/pqa/wa-08/wa0325.htm#17">

  <p>Health Protection Scotland received 4,381 laboratory reports of genital chlamydia for the 3rd quarter of 2007-08, i.e. for the period October to December 2007.</p>

</reply>


<minor-heading id="uk.org.publicwhip/spwa/2008-03-25.S3W-10872.h" nospeaker="True" url="http://www.scottish.parliament.uk/business/pqa/wa-08/wa0325.htm#17">Sexual Health</minor-heading>

<ques id="uk.org.publicwhip/spwa/2008-03-25.S3W-10872.q0" speakerid="uk.org.publicwhip/member/80295" speakername="Jackson Carlaw (West of Scotland) (Con)" spid="S3W-10872" url="http://www.scottish.parliament.uk/business/pqa/wa-08/wa0325.htm#17">

  <p>To ask the Scottish Executive what representations it has made to NHS Quality Improvement Scotland regarding improved recording of repeat testing of individuals for chlamydia in order to improve the accuracy of statistics.</p>

</ques>


<reply id="uk.org.publicwhip/spwa/2008-03-25.S3W-10872.r0" speakerid="uk.org.publicwhip/member/80379" speakername="Shona Robison" url="http://www.scottish.parliament.uk/business/pqa/wa-08/wa0325.htm#17">

  <p><em>Respect and Responsibility</em> , Scotland&rsquo;s national Sexual Health Strategy, allocates actions to NHS Quality Improvement Scotland and to NHS National Services Scotland&rsquo;s Information Services Division to set sexual health standards and to improve data collection of sexually transmitted infections.</p>

</reply>


<minor-heading id="uk.org.publicwhip/spwa/2008-03-25.S3W-10873.h" nospeaker="True" url="http://www.scottish.parliament.uk/business/pqa/wa-08/wa0325.htm#17">Sexual Health</minor-heading>

<ques id="uk.org.publicwhip/spwa/2008-03-25.S3W-10873.q0" speakerid="uk.org.publicwhip/member/80295" speakername="Jackson Carlaw (West of Scotland) (Con)" spid="S3W-10873" url="http://www.scottish.parliament.uk/business/pqa/wa-08/wa0325.htm#17">

  <p>To ask the Scottish Executive what representations it has made to NHS boards regarding improved recording of repeat testing of individuals for chlamydia in order to improve the accuracy of statistics.</p>

</ques>


<reply id="uk.org.publicwhip/spwa/2008-03-25.S3W-10873.r0" speakerid="uk.org.publicwhip/member/80379" speakername="Shona Robison" url="http://www.scottish.parliament.uk/business/pqa/wa-08/wa0325.htm#17">

  <p>Health Protection Scotland, on behalf of the Scottish Government and in association with chlamydia testing laboratories, is exploring ways to develop existing monitoring systems so that a greater understanding of repeat testing among individuals can be achieved.</p>

</reply>


<minor-heading id="uk.org.publicwhip/spwa/2008-03-25.S3W-10874.h" nospeaker="True" url="http://www.scottish.parliament.uk/business/pqa/wa-08/wa0325.htm#17">Sexual Health</minor-heading>

<ques id="uk.org.publicwhip/spwa/2008-03-25.S3W-10874.q0" speakerid="uk.org.publicwhip/member/80295" speakername="Jackson Carlaw (West of Scotland) (Con)" spid="S3W-10874" url="http://www.scottish.parliament.uk/business/pqa/wa-08/wa0325.htm#17">

  <p>To ask the Scottish Executive whether it intends to collect data by NHS board for chlamydia screening in 2008 and how regularly such data is expected to be collected in future years.</p>

</ques>


<reply id="uk.org.publicwhip/spwa/2008-03-25.S3W-10874.r0" speakerid="uk.org.publicwhip/member/80379" speakername="Shona Robison" url="http://www.scottish.parliament.uk/business/pqa/wa-08/wa0325.htm#17">

  <p>Data on chlamydia testing in NHS board areas is collected by Health Protection Scotland to answer the first population key clinical indicators. These were developed as part of the implementation of the sexual health strategy, <em>Respect and Responsibility</em> , the baseline report on the 2005 data was published in February 2006 and the 2006 data has just been published (February 2007). This has become an annual exercise and is expected to continue for the foreseeable future.</p>

</reply>


<minor-heading id="uk.org.publicwhip/spwa/2008-03-25.S3W-10875.h" nospeaker="True" url="http://www.scottish.parliament.uk/business/pqa/wa-08/wa0325.htm#17">Sexual Health</minor-heading>

<ques id="uk.org.publicwhip/spwa/2008-03-25.S3W-10875.q0" speakerid="uk.org.publicwhip/member/80295" speakername="Jackson Carlaw (West of Scotland) (Con)" spid="S3W-10875" url="http://www.scottish.parliament.uk/business/pqa/wa-08/wa0325.htm#17">

  <p>To ask the Scottish Executive what assessment has been made of the success of the Ayrshire and Arran pilot of chlamydia screening through pharmacies.</p>

</ques>


<reply id="uk.org.publicwhip/spwa/2008-03-25.S3W-10875.r0" speakerid="uk.org.publicwhip/member/80379" speakername="Shona Robison" url="http://www.scottish.parliament.uk/business/pqa/wa-08/wa0325.htm#17">

  <p>There has as yet been no formal assessment of the chlamydia testing feasibility study in Ayrshire and Arran. This is due to the small number of community pharmacies and patients which took part.</p>

  <p>NHS Ayrshire and Arran are now planning to increase the number of community pharmacies offering this service and to promote the service with local authority and other health care professionals.</p>

</reply>


<minor-heading id="uk.org.publicwhip/spwa/2008-03-25.S3W-10876.h" nospeaker="True" url="http://www.scottish.parliament.uk/business/pqa/wa-08/wa0325.htm#17">Sexual Health</minor-heading>

<ques id="uk.org.publicwhip/spwa/2008-03-25.S3W-10876.q0" speakerid="uk.org.publicwhip/member/80295" speakername="Jackson Carlaw (West of Scotland) (Con)" spid="S3W-10876" url="http://www.scottish.parliament.uk/business/pqa/wa-08/wa0325.htm#17">

  <p>To ask the Scottish Executive whether it believes that the chlamydia screening targets set out in NHS Quality Improvement Scotland&rsquo;s draft standards are sufficient to meet the aims of its sexual health and relationships strategy on preventing sexually transmitted infections.</p>

</ques>


<reply id="uk.org.publicwhip/spwa/2008-03-25.S3W-10876.r0" speakerid="uk.org.publicwhip/member/80379" speakername="Shona Robison" url="http://www.scottish.parliament.uk/business/pqa/wa-08/wa0325.htm#17">

  <p>The targets for chlamydia testing set out in the draft NHS Quality Improvement Standards have been informed by sexual health key clinical indicators and represent best practice in Scotland.</p>

  <p>The standards represent the minimum level of chlamydia testing which each NHS board will be expected to achieve. We hope NHS boards will exceed these minimum levels as services develop.</p>

</reply>


<minor-heading id="uk.org.publicwhip/spwa/2008-03-25.S3W-10877.h" nospeaker="True" url="http://www.scottish.parliament.uk/business/pqa/wa-08/wa0325.htm#17">Sexual Health</minor-heading>

<ques id="uk.org.publicwhip/spwa/2008-03-25.S3W-10877.q0" speakerid="uk.org.publicwhip/member/80295" speakername="Jackson Carlaw (West of Scotland) (Con)" spid="S3W-10877" url="http://www.scottish.parliament.uk/business/pqa/wa-08/wa0325.htm#17">

  <p>To ask the Scottish Executive what barriers exist to increasing chlamydia screening among men to at least the levels of screening among women and what action could be taken to overcome such barriers.</p>

</ques>


<reply id="uk.org.publicwhip/spwa/2008-03-25.S3W-10877.r0" speakerid="uk.org.publicwhip/member/80379" speakername="Shona Robison" url="http://www.scottish.parliament.uk/business/pqa/wa-08/wa0325.htm#17">

  <p>Generally, men do not access health services as often as women. The reasons for this may be embarrassment, a lack of awareness of the services which are available or not recognising when they may be at risk.</p>

  <p>It is our aim to increase chlamydia testing in men. This can be achieved through a variety of interventions such as better partner notification, young people friendly services including &quot;drop-in&quot; services and testing initiatives targeted at men, provided in venues they regularly attend.</p>

</reply>


<minor-heading id="uk.org.publicwhip/spwa/2008-03-25.S3W-10805.h" nospeaker="True" url="http://www.scottish.parliament.uk/business/pqa/wa-08/wa0325.htm#18">Vaccinations</minor-heading>

<ques id="uk.org.publicwhip/spwa/2008-03-25.S3W-10805.q0" speakerid="uk.org.publicwhip/member/80313" speakername="Murdo Fraser (Mid Scotland and Fife) (Con)" spid="S3W-10805" url="http://www.scottish.parliament.uk/business/pqa/wa-08/wa0325.htm#18">

  <p>To ask the Scottish Executive what action it will take in light of the judgement by the US Attorney General on behalf of the Department of Health and Human Services which found that combined multiple vaccinations received by a child significantly aggravated an underlying mitochondrial disorder predisposing her to deficits in cellular energy metabolism and manifested as a regressive encephalopathy with features of autism.</p>

</ques>


<reply id="uk.org.publicwhip/spwa/2008-03-25.S3W-10805.r0" speakerid="uk.org.publicwhip/member/80379" speakername="Shona Robison" url="http://www.scottish.parliament.uk/business/pqa/wa-08/wa0325.htm#18">

  <p>The details of the judgement in this case are sealed and much of what is being publicly suggested is speculation. What is known is that the child in question has an extremely rare genetic metabolic condition and as part of her neurological signs and symptoms, she has autistic-like features. There is a wealth of scientific evidence that vaccines do not cause autism and the circumstances of this case do not change that conclusion.</p>

</reply>


<minor-heading id="uk.org.publicwhip/spwa/2008-03-25.S3W-10806.h" nospeaker="True" url="http://www.scottish.parliament.uk/business/pqa/wa-08/wa0325.htm#18">Vaccinations</minor-heading>

<ques id="uk.org.publicwhip/spwa/2008-03-25.S3W-10806.q0" speakerid="uk.org.publicwhip/member/80313" speakername="Murdo Fraser (Mid Scotland and Fife) (Con)" spid="S3W-10806" url="http://www.scottish.parliament.uk/business/pqa/wa-08/wa0325.htm#18">

  <p>To ask the Scottish Executive whether it will take steps to screen out all children with mitochondrial dysfunction from the vaccination programme.</p>

</ques>


<reply id="uk.org.publicwhip/spwa/2008-03-25.S3W-10806.r0" speakerid="uk.org.publicwhip/member/80379" speakername="Shona Robison" url="http://www.scottish.parliament.uk/business/pqa/wa-08/wa0325.htm#18">

  <p>The details of the judgement in this case are sealed and much of what is being publicly suggested is speculation. What is known is that the child in question has an extremely rare genetic metabolic condition and as part of her neurological signs and symptoms, she has autistic-like features. At the same time there is a wealth of scientific evidence that vaccines do not cause autism. Therefore there are no plans to take any steps to screen out all children with mitochondrial dysfunction from the routine childhood vaccination programme.</p>

</reply>


<minor-heading id="uk.org.publicwhip/spwa/2008-03-25.S3W-10808.h" nospeaker="True" url="http://www.scottish.parliament.uk/business/pqa/wa-08/wa0325.htm#18">Vaccinations</minor-heading>

<ques id="uk.org.publicwhip/spwa/2008-03-25.S3W-10808.q0" speakerid="uk.org.publicwhip/member/80313" speakername="Murdo Fraser (Mid Scotland and Fife) (Con)" spid="S3W-10808" url="http://www.scottish.parliament.uk/business/pqa/wa-08/wa0325.htm#18">

  <p>To ask the Scottish Executive whether it will take steps to introduce single vaccines in place of combined vaccines as a choice to parents.</p>

</ques>


<reply id="uk.org.publicwhip/spwa/2008-03-25.S3W-10808.r0" speakerid="uk.org.publicwhip/member/80379" speakername="Shona Robison" url="http://www.scottish.parliament.uk/business/pqa/wa-08/wa0325.htm#18">

  <p>The childhood immunisation programme in Scotland does not offer single vaccines routinely and there are no plans to change this policy. Offering single vaccines, with time lags of a month or more between the three, would leave a child at risk from mumps, measles or rubella. This also has an impact upon herd immunity (where vaccination of a proportion of the population provides protection to unvaccinated individuals) and may mean those children that cannot be vaccinated for medical reasons would be at increased risk of the disease.</p>

  <p>The combined MMR vaccine has been in use for a period of nearly 30 years, with over 500 million doses given in over 100 countries. Based on the findings from the on-going monitoring of its safety, and the evidence from the wide range of scientific investigations into the speculated risks to health, the vaccine has an excellent safety record.</p>

</reply>


<minor-heading id="uk.org.publicwhip/spwa/2008-03-25.S3W-10809.h" nospeaker="True" url="http://www.scottish.parliament.uk/business/pqa/wa-08/wa0325.htm#18">Vaccinations</minor-heading>

<ques id="uk.org.publicwhip/spwa/2008-03-25.S3W-10809.q0" speakerid="uk.org.publicwhip/member/80313" speakername="Murdo Fraser (Mid Scotland and Fife) (Con)" spid="S3W-10809" url="http://www.scottish.parliament.uk/business/pqa/wa-08/wa0325.htm#18">

  <p>To ask the Scottish Executive whether it will undertake research to discover whether combined multiple vaccines can aggravate underlying medical conditions leading to features of autistic spectrum disorder.</p>

</ques>


<reply id="uk.org.publicwhip/spwa/2008-03-25.S3W-10809.r0" speakerid="uk.org.publicwhip/member/80379" speakername="Shona Robison" url="http://www.scottish.parliament.uk/business/pqa/wa-08/wa0325.htm#18">

  <p>There is a wealth of scientific evidence that vaccines do not cause autism and as such there are no plans to undertake any further research in this area. The Scottish Government and the Medical Research Council (MRC) have however taken forward a jointly funded research programme in relation to autism, based on the agenda outlined in the MRC Review of Autism Research. The MRC has now committed over &pound;3 million to new research. The awards range from clinical investigations in children and adults, to environmental risk factors, brain imaging and intervention studies. The Chief Scientist Office has also funded a number of studies into autism.</p>

</reply>


<major-heading id="uk.org.publicwhip/spwa/2008-03-25.2.mh" nospeaker="True" url="http://www.scottish.parliament.uk/business/pqa/wa-08/wa0325.htm#18">Scottish Parliamentary Corporate Body</major-heading>

<minor-heading id="uk.org.publicwhip/spwa/2008-03-25.S3W-10645.h" nospeaker="True" url="http://www.scottish.parliament.uk/business/pqa/wa-08/wa0325.htm#19">Information Technology</minor-heading>

<ques id="uk.org.publicwhip/spwa/2008-03-25.S3W-10645.q0" speakerid="uk.org.publicwhip/member/80321" speakername="Christine Grahame (South of Scotland) (SNP)" spid="S3W-10645" url="http://www.scottish.parliament.uk/business/pqa/wa-08/wa0325.htm#19" holdingdate="2008-03-11">

  <p>To ask the Scottish Parliamentary Corporate Body how many IT incidents have been recorded where parliamentary account users have been unable to log on remotely from home or constituency offices due to problems associated with lack of capacity on parliamentary servers.</p>

</ques>


<reply id="uk.org.publicwhip/spwa/2008-03-25.S3W-10645.r0" speakerid="uk.org.publicwhip/member/80333" speakername="Alex Johnstone" url="http://www.scottish.parliament.uk/business/pqa/wa-08/wa0325.htm#19">

  <p>IT incidents have been categorised since December 2005. The table below shows the number of IT incidents logged with the Helpdesk per month where the user has been unable to connect to the Parliament remotely due to capacity issues.</p>

  <p><table width="50%" border="BORDER" cellpadding="2" cellspacing="0" bordercolor="#CCCCCC">
<tr>
<td width="31%" valign="top"> </td>
<td width="17%" align="center" valign="top"> 2005</td>
<td width="17%" align="center" valign="top"> 2006</td>
<td width="17%" align="center" valign="top"> 2007</td>
<td width="17%" align="center" valign="top"> 2008</td>
</tr>
<tr>
<td width="31%" align="left" valign="top"> January</td>
<td width="17%" align="right" valign="top"> </td>
<td width="17%" align="right" valign="top"> 8</td>
<td width="17%" align="right" valign="top"> 3</td>
<td width="17%" align="right" valign="top"> 7</td>
</tr>
<tr>
<td width="31%" align="left" valign="top"> February</td>
<td width="17%" align="right" valign="top"> </td>
<td width="17%" align="right" valign="top"> 17</td>
<td width="17%" align="right" valign="top"> 5</td>
<td width="17%" align="right" valign="top"> 35</td>
</tr>
<tr>
<td width="31%" align="left" valign="top"> March</td>
<td width="17%" align="right" valign="top"> </td>
<td width="17%" align="right" valign="top"> 29</td>
<td width="17%" align="right" valign="top"> 20</td>
<td width="17%" align="right" valign="top"> 102</td>
</tr>
<tr>
<td width="31%" align="left" valign="top"> April</td>
<td width="17%" align="right" valign="top"> </td>
<td width="17%" align="right" valign="top"> 1</td>
<td width="17%" align="right" valign="top"> 0</td>
<td width="17%" align="right" valign="top"> </td>
</tr>
<tr>
<td width="31%" align="left" valign="top"> May</td>
<td width="17%" align="right" valign="top"> </td>
<td width="17%" align="right" valign="top"> 0</td>
<td width="17%" align="right" valign="top"> 0</td>
<td width="17%" align="right" valign="top"> </td>
</tr>
<tr>
<td width="31%" align="left" valign="top"> June</td>
<td width="17%" align="right" valign="top"> </td>
<td width="17%" align="right" valign="top"> 48</td>
<td width="17%" align="right" valign="top"> 1</td>
<td width="17%" align="right" valign="top"> </td>
</tr>
<tr>
<td width="31%" align="left" valign="top"> July</td>
<td width="17%" align="right" valign="top"> </td>
<td width="17%" align="right" valign="top"> 2</td>
<td width="17%" align="right" valign="top"> 0</td>
<td width="17%" align="right" valign="top"> </td>
</tr>
<tr>
<td width="31%" align="left" valign="top"> August</td>
<td width="17%" align="right" valign="top"> </td>
<td width="17%" align="right" valign="top"> 10</td>
<td width="17%" align="right" valign="top"> 1</td>
<td width="17%" align="right" valign="top"> </td>
</tr>
<tr>
<td width="31%" align="left" valign="top"> September</td>
<td width="17%" align="right" valign="top"> </td>
<td width="17%" align="right" valign="top"> 2</td>
<td width="17%" align="right" valign="top"> 0</td>
<td width="17%" align="right" valign="top"> </td>
</tr>
<tr>
<td width="31%" align="left" valign="top"> October</td>
<td width="17%" align="right" valign="top"> </td>
<td width="17%" align="right" valign="top"> 6</td>
<td width="17%" align="right" valign="top"> 7</td>
<td width="17%" align="right" valign="top"> </td>
</tr>
<tr>
<td width="31%" align="left" valign="top"> November</td>
<td width="17%" align="right" valign="top"> </td>
<td width="17%" align="right" valign="top"> 1</td>
<td width="17%" align="right" valign="top"> 4</td>
<td width="17%" align="right" valign="top"> </td>
</tr>
<tr>
<td width="31%" align="left" valign="top"> December</td>
<td width="17%" align="right" valign="top"> 4</td>
<td width="17%" align="right" valign="top"> 0</td>
<td width="17%" align="right" valign="top"> 6</td>
<td width="17%" align="right" valign="top"> </td>
</tr>
</table></p>

</reply>
</publicwhip>